



- (51) International Patent Classification:
C12P 21/06 (2006.01) C12N 15/00 (2006.01)
- (21) International Application Number:
PCT/US2011/061164
- (22) International Filing Date:
17 November 2011 (17.11.2011)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/414,850 17 November 2010 (17.11.2010) US
- (71) Applicants (for all designated States except US): **ADURO BIOTECH** [US/US]; 626 Bancroft Way, Suite 3c, Berkeley, CA 94710-2225 (US). **PROVIDENCE HEALTH & SERVICES-OREGON D/B/A PROVIDENCE PORTLAND MEDICAL CENTER** [US/US]; 4805 N.E. Glison Street, Portland, OR 97213 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LAUER, Peter, M.** [US/US]; 1003 Solano Avenue, Albany, CA 94706 (US). **BAHJAT, Keith** [US/US]; 7025 Nw Summitview Drive, Portland, OR 97229 (US).
- (74) Agents: **WHITTAKER, Michael, A.** et al.; Acuity Law Group, P.C., 12707 High Bluf Drive, Suite 200, San Diego, CA 92130 (US).


- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO EGFRvIII

Fig. 1



(57) Abstract: The present invention relates to methods of inducing a T-cell response against a EGFRvIII in a subject. These methods comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), and/or administering the polypeptide itself.

WO 2012/068360 A1

METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE
TO EGFRvIII

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] The present invention claims priority from United States Provisional Patent Application No. 61/414,850, filed November 17, 2010, which is hereby incorporated in its entirety, including all tables, figures and claims.

BACKGROUND OF THE INVENTION

[0002] The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the present invention.

[0003] The EGFR3 gene (c-erbB-1) is often amplified and overexpressed in malignant human tissues. Frequently, this amplification is correlated with structural rearrangement of the gene, resulting in in-frame deletion-mutants deficient in the intracellular and transmembrane domains of wild-type c-erb-1. One class of deletion-mutant identified in some malignant gliomas and non-small cell lung carcinomas is referred to as EGFRvIII. EGFRvIII is a mutation in which amino acids 6–273 (in the extracellular domain, with residue 1 being the residue immediately following the signal sequence) are deleted, and a glycine is inserted between residues 5 and 274. The sequence of the N-terminal 10 residues of the EGFRvIII mutation is LEEKKGNYVV (SEQ ID NO: 1).

[0004] Patients with EGFRvIII expressing breast cancers have detectable humoral and cellular immune responses against this peptide, suggesting that it serves as an immunogenic neo-antigen. A 13 amino acid peptide from this junction (LEEKKGNYVVTDH; SEQ ID NO: 2), referred to as PEPvIII, has been used to vaccinate humans with EGFRvIII-expressing tumors. In a recently published study, PEPvIII conjugated to KLH was administered to newly diagnosed glioblastoma multiforme (“GBM”) patients treated by gross total resection (>95%), radiation and temozolomide who had no radiographic evidence of progression. Humoral immune responses to EGFRvIII were observed in 6 of 14 immunized patients, while 3 of 17 showed a positive DTH response. The median overall survival for patients treated with

vaccine and temozolomide was 26.0 months from the time of histologic diagnosis, versus 15.0 months for a matched cohort receiving only temozolomide. These encouraging results support the utility of EGFRvIII-expressing vaccines and suggest that a more potent vaccine, one that elicits a robust, durable and potent antigen-specific T cell response, could improve the magnitude and duration of the anti-EGFRvIII response.

[0005] *Listeria monocytogenes* is a gram-positive intracellular bacterium being explored for its utility as a vaccine vector. Infection with *L. monocytogenes* elicits a potent CD8+ T cell response, necessary for the killing of *L. monocytogenes*-infected cells and control of infection. Attenuation of *L. monocytogenes* improves the safety of the vector 100-1,000 fold while maintaining or enhancing its immunogenicity. The ease with which the vector can be genetically manipulated, together with the straightforward production methodologies make *L. monocytogenes* an attractive platform for cancer vaccines.

[0006] There remains a need in the art for compositions and methods for stimulating an effective immune response to of EGFRvIII-expressing malignancies.

BRIEF SUMMARY OF THE INVENTION

[0007] The present invention provides compositions and methods for delivery of a multimeric EGFRvIII antigen vaccine using a bacterium recombinantly encoding and expressing such antigens.

[0008] In a first aspect of the invention, the invention relates to methods of inducing a T-cell response against EGFRvIII in a subject. These method comprise administering to a subject a composition comprising a bacterium which expresses one or more immunogenic polypeptides, the amino acid sequence of which comprise a plurality (2, 3, 4, 5, or more copies) of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3). In certain embodiments, these EGFRvIII-derived sequences can comprise or consist of LEEKKGNYV (SEQ ID NO: 4), LEEKKGNYVVDH (SEQ ID NO: 2), or PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5). As described hereinafter, most preferred are *L. monocytogenes* bacterium expressing the immunogenic polypeptide(s) described herein.

[0009] As also described herein, such methods can stimulate an immune response, including one or more of a humoral response and antigen-specific T cell (CD4+ and/or CD8+) response, in said subject to the recombinantly expressed EGFRvIII polypeptides. The ability of such polypeptides to generate a CD4+ and/or CD8+ T cell response may be confirmed by a variety of methods described in detail herein and that are well known in the art. Preferably, when delivered to the subject, the compositions of the present invention induce an increase in the serum concentration of one or more, and preferably each of, proteins selected from the group consisting of IL-12p70, IFN- γ , IL-6, TNF α , and MCP-1 at 24 hours following said delivery; and induce a CD4+ and/or CD8+ antigen-specific T cell response against EGFRvIII.

[0010] In a related aspect of the invention, the invention relates to compositions useful for inducing a T-cell response against EGFRvIII in a subject. Such compositions comprise a bacterium which comprises a nucleic acid molecule, the sequence of which encodes one or more immunogenic polypeptides, the amino acid sequence of which comprise a plurality (2, 3, 4, 5, or more copies) of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3). In certain embodiments, these EGFRvIII-derived sequences can comprise or consist of LEEKKGNYV (SEQ ID NO: 4), LEEKKGNYVVDH (SEQ ID NO: 2), or PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5). As described hereinafter, most preferred are *L. monocytogenes* bacterium expressing the immunogenic polypeptide(s) described herein. In certain embodiments, the nucleic acid sequences encoding the EGFRvIII-derived sequences are codon optimized for expression in the desired bacterium.

[0011] In another related aspect, the invention relates to a isolated nucleic acid molecule, the sequence of which encodes one or more immunogenic polypeptides, the amino acid sequence of which comprise a plurality (2, 3, 4, 5, or more copies) of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), or the corresponding polypeptides themselves. In certain embodiments, these EGFRvIII-derived sequences can comprise or consist of LEEKKGNYV (SEQ ID NO: 4), LEEKKGNYVVDH (SEQ ID NO: 2), or PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).

[0012] Methods for deriving appropriate immunogenic polypeptide sequences are described in detail hereinafter. In certain embodiments, at least two of the EGFRvIII polypeptide sequences are separated by a polypeptide linker which is configured to be processed by proteases present in the subject. By way of example, one EGFRvIII polypeptide sequence may be separated from an adjacent EGFR polypeptide sequence by a sequence which is configured to be cleaved by the proteasome. In certain embodiments, each EGFRvIII polypeptide sequence is flanked by (and thereby separated from adjacent EGFR polypeptide sequence(s)) a sequence which is configured to be cleaved by the proteasome. Suitable polypeptide sequences, and the nucleic acid sequences encoding them, are described in detail hereinafter.

[0013] In certain embodiments, the immunogenic polypeptide(s) comprise one or more “cleavable” amino acid sequences selected from the group consisting of ASKVL↓ADGSVK; ASKVA↓GDGSIK; LSKVL↓ADGSVK; LAKSL↓ADLAVK; ASVVA↓GIGSIA; GVEKI↓NAANKG; and DGSKKA↓GDGNKK (SEQ ID NOS: 6-12). In these sequences, the antigenic sequence is placed at the location indicated by the arrow, such that the “cleavable” amino acid sequence flanks the antigenic sequence. These sequences may be combined such that any sequence to the left of an arrow may be combined with any sequence to the right of an arrow to create a new flanking pair.

[0014] One may also create strings of these sequences such as ASKVL↓ADGSVKASKVA↓GDGSIKLSKVL↓ADGSVKASKVA↓GDGSIKLSKVL↓ADGSVK (SEQ ID NO: 13), again in which the antigenic sequence is placed at the location indicated by the arrow. In an effort to improve clarity, this listing shows the first flanking sequence underlined, the second not underlined, the third underlined, the fourth not underlined, and the fifth underlined. Another example is ASKVL↓ADGSVKDGSKKA↓GDGNKKLSKVL↓ADGSVKDGSKKA↓GDGNKKLSKVL↓ADGSVKDGSKKA↓GDGNKK (SEQ ID NO: 14). These sequences are exemplary in nature only. Suitable proteasomal cleavage motifs are described in detail in Toes et al., J. Exp. Med. 194: 1-12, 2001, which is hereby incorporated by reference in its entirety. See also, Lauer et al., Infect. Immun. 76: 3742-53, 2008; and Sinnathamby et al., (J. Immunother. 32: 856–69, 2009).

[0015] A number of bacterial species have been developed for use as vaccines and can be used as a vaccine platform in present invention, including, but not limited to,

Shigella flexneri, *Escherichia coli*, *Listeria monocytogenes*, *Yersinia enterocolitica*, *Salmonella typhimurium*, *Salmonella typhi* or *mycobacterium species*. This list is not meant to be limiting. The present invention contemplates the use of attenuated, commensal, and/or killed but metabolically active bacterial strains as vaccine platforms. In preferred embodiments the bacterium is *Listeria monocytogenes* comprising a nucleic acid sequence encoding for expression by the bacterium of the EGFRvIII polypeptide sequences of the invention. This nucleic acid is most preferably integrated into the genome of the bacterium. Attenuated and killed but metabolically active forms of *Listeria monocytogenes* are particularly preferred, and *Listeria monocytogenes* harboring an attenuating mutation in *actA* and/or *inlB* is described hereinafter in preferred embodiments. While the present invention is described herein with regard to bacterial vectors, suitable agents for delivery of a target antigen include additional recombinant vectors, for example, viruses, and naked DNA.

[0016] The vaccine compositions described herein can be administered to a host, either alone or in combination with a pharmaceutically acceptable excipient, in an amount sufficient to induce an appropriate immune response to prevent or treat a malignancy associated with EGFRvIII expression. Preferred conditions selected to induce a T cell response in a subject comprise administering the vaccine platform intravenously to a subject; however, administration may be oral, intravenous, subcutaneous, dermal, intradermal, intramuscular, mucosal, parenteral, intraorgan, intralesional, intranasal, inhalation, intraocular, intravascular, intranodal, by scarification, rectal, intraperitoneal, or any one or combination of a variety of well-known routes of administration.

[0017] In certain preferred embodiments, after the subject has been administered an effective dose of a vaccine containing the immunogenic polypeptides to prime the immune response, a second vaccine is administered. This is referred to in the art as a “prime-boost” regimen. In such a regimen, the compositions and methods of the present invention may be used as the “prime” delivery, as the “boost” delivery, or as both a “prime” and a “boost.” Examples of such regimens are described hereinafter.

[0018] A preferred *Listeria monocytogenes* for use in the present invention comprises a mutation in the *prfA* gene which locks the expressed *prfA* transcription factor into a constitutively active state. For example, a *PrfA** mutant (G155S) has been shown to

enhance functional cellular immunity following a prime-boost intravenous or intramuscular immunization regimen.

[0019] In certain embodiments, the EGFRvIII polypeptide sequences of the present invention are expressed as a fusion protein comprising an in frame secretory signal sequence, thereby resulting in their secretion as soluble polypeptide(s) by the bacterium. Numerous exemplary signal sequences are known in the art for use in bacterial expression systems. In the case where the bacterium is *Listeria monocytogenes*, it is preferred that the secretory signal sequence is a *Listeria monocytogenes* signal sequence, most preferably the ActA signal sequence. Additional ActA or other linker amino acids may also be expressed fused to the immunogenic polypeptide(s). In preferred embodiments, one or more immunogenic polypeptide(s) are expressed as fusion protein(s) comprising an in frame ActA-N100 sequence (*e.g.*, selected from the group consisting of SEQ ID NO: 37, 38 and 39) or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence.

[0020] In preferred embodiments, the vaccine composition comprises a *Listeria monocytogenes* expressing a fusion protein comprising:

(a) an ActA-N100 sequence selected from the group consisting of SEQ ID NO: 37, 38 and 39, or an amino acid sequence having at least 90% sequence identity to such a ActA-N100 sequence;

(b) an amino acid sequence comprising a plurality (2, 3, 4, 5, or more copies) of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3); and

(c) a linker amino acid sequence positioned between at least two of the EGFRvIII polypeptide sequences, wherein the linker amino acid sequence is configured for proteasomal cleavage,

wherein the fusion protein is expressed from a nucleic acid sequence operably linked to a *Listeria monocytogenes* ActA promoter.

[0021] In another aspect, the present invention relates to a method of evaluating an EGFRvIII immune response in a mouse model system. These methods comprise

immunizing a mouse with an EGFRvIII polypeptide, and assessing the resulting EGFRvIII-specific immune response by determining reactivity to a polypeptide, the sequence of which consists of EEKKGNYV.

[0022] As noted above, in certain embodiments the nucleic acid sequences encoding the antigenic polypeptide(s) are codon optimized for expression by the bacterium (e.g., *Listeria monocytogenes*). As described hereinafter, different organisms often display “codon bias”; that is, the degree to which a given codon encoding a particular amino acid appears in the genetic code varies significantly between organisms. In general, the more rare codons that a gene contains, the less likely it is that the heterologous protein will be expressed at a reasonable level within that specific host system. These levels become even lower if the rare codons appear in clusters or in the N-terminal portion of the protein. Replacing rare codons with others that more closely reflect the host system's codon bias without modifying the amino acid sequence can increase the levels of functional protein expression. Methods for codon optimization are described hereinafter.

[0023] It is to be understood that the invention is not limited in its application to the details of construction and to the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of embodiments in addition to those described and of being practiced and carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein, as well as the abstract, are for the purpose of description and should not be regarded as limiting.

[0024] As such, those skilled in the art will appreciate that the conception upon which this disclosure is based may readily be utilized as a basis for the designing of other structures, methods and systems for carrying out the several purposes of the present invention. It is important, therefore, that the claims be regarded as including such equivalent constructions insofar as they do not depart from the spirit and scope of the present invention.

BRIEF DESCRIPTION OF THE FIGURES

[0025] Fig. 1 schematically depicts exemplary expression cassettes for use in the present invention.

[0026] Fig. 2 depicts Western blot results demonstrating expression of EGFRvIII antigens by recombinant *Listeria*.

[0027] Fig. 3 depicts EGFRvIII antigen-specific CD8+ T cells induced by immunization with recombinant *Listeria*.

[0028] Fig. 4 depicts the results obtained from a B3Z T cell activation assay following immunization with recombinant *Listeria*.

[0029] Fig. 5 depicts the results obtained from screening of CD8+ T cells for reactivity against specific EGFRvIII peptides following immunization with recombinant *Listeria*.

[0030] Fig. 6 depicts the results obtained from a T2 cell assay measuring induction of class I expression upon EGFRvIII peptide binding.

[0031] Fig. 7 depicts enhanced CD8+ T cell priming following immunization with recombinant *Listeria* expressing multiple copies of EGFRvIII20-40, relative to the single copy variant.

DETAILED DESCRIPTION OF THE INVENTION

[0032] The present invention relates to compositions and methods for delivery of immunotherapy using a bacterium encoding and expressing a plurality of copies of an antigen derived from EGFRvIII.

[0033] It is to be understood that the invention is not limited in its application to the details of construction and to the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of embodiments in addition to those described and of being practiced and carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein, as well as the abstract, are for the purpose of description and should not be regarded as limiting.

[0034] As such, those skilled in the art will appreciate that the conception upon which this disclosure is based may readily be utilized as a basis for the designing of other structures, methods and systems for carrying out the several purposes of the present

invention. It is important, therefore, that the claims be regarded as including such equivalent constructions insofar as they do not depart from the spirit and scope of the present invention.

[0035] 1. Definitions

[0036] Abbreviations used to indicate a mutation in a gene, or a mutation in a bacterium comprising the gene, are as follows. By way of example, the abbreviation “*L. monocytogenes* $\Delta actA$ ” means that part, or all, of the *actA* gene was deleted. The delta symbol (Δ) means deletion. An abbreviation including a superscripted minus sign (*Listeria ActA*⁻) means that the *actA* gene was mutated, *e.g.*, by way of a deletion, point mutation, or frameshift mutation, but not limited to these types of mutations.

[0037] “Administration” as it applies to a human, mammal, mammalian subject, animal, veterinary subject, placebo subject, research subject, experimental subject, cell, tissue, organ, or biological fluid, refers without limitation to contact of an exogenous ligand, reagent, placebo, small molecule, pharmaceutical agent, therapeutic agent, diagnostic agent, or composition to the subject, cell, tissue, organ, or biological fluid, and the like. “Administration” can refer, *e.g.*, to therapeutic, pharmacokinetic, diagnostic, research, placebo, and experimental methods. Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell. “Administration” also encompasses *in vitro* and *ex vivo* treatments, *e.g.*, of a cell, by a reagent, diagnostic, binding composition, or by another cell.

[0038] An “agonist,” as it relates to a ligand and receptor, comprises a molecule, combination of molecules, a complex, or a combination of reagents, that stimulates the receptor. For example, an agonist of granulocyte-macrophage colony stimulating factor (GM-CSF) can encompass GM-CSF, a mutein or derivative of GM-CSF, a peptide mimetic of GM-CSF, a small molecule that mimics the biological function of GM-CSF, or an antibody that stimulates GM-CSF receptor.

[0039] An “antagonist,” as it relates to a ligand and receptor, comprises a molecule, combination of molecules, or a complex, that inhibits, counteracts, downregulates, and/or desensitizes the receptor. “Antagonist” encompasses any reagent that inhibits a constitutive activity of the receptor. A constitutive activity is one that is manifest in the absence of a ligand/receptor interaction. “Antagonist” also encompasses any reagent that

inhibits or prevents a stimulated (or regulated) activity of a receptor. By way of example, an antagonist of GM-CSF receptor includes, without implying any limitation, an antibody that binds to the ligand (GM-CSF) and prevents it from binding to the receptor, or an antibody that binds to the receptor and prevents the ligand from binding to the receptor, or where the antibody locks the receptor in an inactive conformation.

[0040] As used herein, an “analog” or “derivative” with reference to a peptide, polypeptide or protein refers to another peptide, polypeptide or protein that possesses a similar or identical function as the original peptide, polypeptide or protein, but does not necessarily comprise a similar or identical amino acid sequence or structure of the original peptide, polypeptide or protein. An analog preferably satisfies at least one of the following: (a) a proteinaceous agent having an amino acid sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the original amino acid sequence (b) a proteinaceous agent encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding the original amino acid sequence; and (c) a proteinaceous agent encoded by a nucleotide sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the nucleotide sequence encoding the original amino acid sequence.

[0041] “Antigen presenting cells” (APCs) are cells of the immune system used for presenting antigen to T cells. APCs include dendritic cells, monocytes, macrophages, marginal zone Kupffer cells, microglia, Langerhans cells, T cells, and B cells. Dendritic cells occur in at least two lineages. The first lineage encompasses pre-DC1, myeloid DC1, and mature DC1. The second lineage encompasses CD34⁺CD45RA⁻ early progenitor multipotent cells, CD34⁺CD45RA⁺ cells, CD34⁺CD45RA⁺CD4⁺ IL-3Rα⁺ pro-DC2 cells, CD4⁺CD11c⁻ plasmacytoid pre-DC2 cells, lymphoid human DC2 plasmacytoid-derived DC2s, and mature DC2s.

[0042] “Attenuation” and “attenuated” encompasses a bacterium, virus, parasite, infectious organism, prion, tumor cell, gene in the infectious organism, and the like, that is modified to reduce toxicity to a host. The host can be a human or animal host, or an organ, tissue, or cell. The bacterium, to give a non-limiting example, can be attenuated to

reduce binding to a host cell, to reduce spread from one host cell to another host cell, to reduce extracellular growth, or to reduce intracellular growth in a host cell. Attenuation can be assessed by measuring, e.g., an indicum or indicia of toxicity, the LD₅₀, the rate of clearance from an organ, or the competitive index (see, e.g., Auerbuch, *et al.* (2001) *Infect. Immunity* 69:5953-5957). Generally, an attenuation results an increase in the LD₅₀ and/or an increase in the rate of clearance by at least 25%; more generally by at least 50%; most generally by at least 100% (2-fold); normally by at least 5-fold; more normally by at least 10-fold; most normally by at least 50-fold; often by at least 100-fold; more often by at least 500-fold; and most often by at least 1000-fold; usually by at least 5000-fold; more usually by at least 10,000-fold; and most usually by at least 50,000-fold; and most often by at least 100,000-fold.

[0043] “Attenuated gene” encompasses a gene that mediates toxicity, pathology, or virulence, to a host, growth within the host, or survival within the host, where the gene is mutated in a way that mitigates, reduces, or eliminates the toxicity, pathology, or virulence. The reduction or elimination can be assessed by comparing the virulence or toxicity mediated by the mutated gene with that mediated by the non-mutated (or parent) gene. “Mutated gene” encompasses deletions, point mutations, and frameshift mutations in regulatory regions of the gene, coding regions of the gene, non-coding regions of the gene, or any combination thereof.

[0044] “Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, a conservatively modified variant refers to nucleic acids encoding identical amino acid sequences, or amino acid sequences that have one or more conservative substitutions. An example of a conservative substitution is the exchange of an amino acid in one of the following groups for another amino acid of the same group (U.S. Pat. No. 5,767,063 issued to Lee, *et al.*; Kyte and Doolittle (1982) *J. Mol. Biol.* 157:105-132).

- (1) Hydrophobic: Norleucine, Ile, Val, Leu, Phe, Cys, Met;
- (2) Neutral hydrophilic: Cys, Ser, Thr;
- (3) Acidic: Asp, Glu;
- (4) Basic: Asn, Gln, His, Lys, Arg;
- (5) Residues that influence chain orientation: Gly, Pro;
- (6) Aromatic: Trp, Tyr, Phe; and

(7) Small amino acids: Gly, Ala, Ser.

[0045] “Effective amount” encompasses, without limitation, an amount that can ameliorate, reverse, mitigate, prevent, or diagnose a symptom or sign of a medical condition or disorder. Unless dictated otherwise, explicitly or by context, an “effective amount” is not limited to a minimal amount sufficient to ameliorate a condition.

[0046] An “extracellular fluid” encompasses, e.g., serum, plasma, blood, interstitial fluid, cerebrospinal fluid, secreted fluids, lymph, bile, sweat, fecal matter, and urine. An “extracellular fluid” can comprise a colloid or a suspension, e.g., whole blood or coagulated blood.

[0047] The term “fragments” in the context of polypeptides include a peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino acid residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least 200 contiguous amino acid residues, or at least 250 contiguous amino acid residues of the amino acid sequence of a larger polypeptide.

[0048] “Gene” refers to a nucleic acid sequence encoding an oligopeptide or polypeptide. The oligopeptide or polypeptide can be biologically active, antigenically active, biologically inactive, or antigenically inactive, and the like. The term gene encompasses, e.g., the sum of the open reading frames (ORFs) encoding a specific oligopeptide or polypeptide; the sum of the ORFs plus the nucleic acids encoding introns; the sum of the ORFs and the operably linked promoter(s); the sum of the ORFs and the operably linked promoter(s) and any introns; the sum of the ORFs and the operably linked promoter(s), intron(s), and promoter(s), and other regulatory elements, such as enhancer(s). In certain embodiments, “gene” encompasses any sequences required in cis for regulating expression of the gene. The term gene can also refer to a nucleic acid that encodes a peptide encompassing an antigen or an antigenically active fragment of a

peptide, oligopeptide, polypeptide, or protein. The term gene does not necessarily imply that the encoded peptide or protein has any biological activity, or even that the peptide or protein is antigenically active. A nucleic acid sequence encoding a non-expressible sequence is generally considered a pseudogene. The term gene also encompasses nucleic acid sequences encoding a ribonucleic acid such as rRNA, tRNA, or a ribozyme.

[0049] “Growth” of a bacterium such as *Listeria* encompasses, without limitation, functions of bacterial physiology and genes relating to colonization, replication, increase in protein content, and/or increase in lipid content. Unless specified otherwise explicitly or by context, growth of a *Listeria* encompasses growth of the bacterium outside a host cell, and also growth inside a host cell. Growth related genes include, without implying any limitation, those that mediate energy production (e.g., glycolysis, Krebs cycle, cytochromes), anabolism and/or catabolism of amino acids, sugars, lipids, minerals, purines, and pyrimidines, nutrient transport, transcription, translation, and/or replication. In some embodiments, “growth” of a *Listeria* bacterium refers to intracellular growth of the *Listeria* bacterium, that is, growth inside a host cell such as a mammalian cell. While intracellular growth of a *Listeria* bacterium can be measured by light microscopy or colony forming unit (CFU) assays, growth is not to be limited by any technique of measurement. Biochemical parameters such as the quantity of a *Listerial* antigen, *Listerial* nucleic acid sequence, or lipid specific to the *Listeria* bacterium, can be used to assess growth. In some embodiments, a gene that mediates growth is one that specifically mediates intracellular growth. In some embodiments, a gene that specifically mediates intracellular growth encompasses, but is not limited to, a gene where inactivation of the gene reduces the rate of intracellular growth but does not detectably, substantially, or appreciably, reduce the rate of extracellular growth (e.g., growth in broth), or a gene where inactivation of the gene reduces the rate of intracellular growth to a greater extent than it reduces the rate of extracellular growth. To provide a non-limiting example, in some embodiments, a gene where inactivation reduces the rate of intracellular growth to a greater extent than extracellular growth encompasses the situation where inactivation reduces intracellular growth to less than 50% the normal or maximal value, but reduces extracellular growth to only 1-5%, 5-10%, or 10-15% the maximal value. The invention, in certain aspects, encompasses a *Listeria* attenuated in intracellular growth but not attenuated in extracellular growth, a *Listeria* not attenuated in intracellular growth and not

attenuated in extracellular growth, as well as a *Listeria* not attenuated in intracellular growth but attenuated in extracellular growth.

[0050] A “hydropathy analysis” refers to the analysis of a polypeptide sequence by the method of Kyte and Doolittle: "A Simple Method for Displaying the Hydropathic Character of a Protein". J. Mol. Biol. 157(1982)105-132. In this method, each amino acid is given a hydrophobicity score between 4.6 and -4.6. A score of 4.6 is the most hydrophobic and a score of -4.6 is the most hydrophilic. Then a window size is set. A window size is the number of amino acids whose hydrophobicity scores will be averaged and assigned to the first amino acid in the window. The calculation starts with the first window of amino acids and calculates the average of all the hydrophobicity scores in that window. Then the window moves down one amino acid and calculates the average of all the hydrophobicity scores in the second window. This pattern continues to the end of the protein, computing the average score for each window and assigning it to the first amino acid in the window. The averages are then plotted on a graph. The y axis represents the hydrophobicity scores and the x axis represents the window number. The following hydrophobicity scores are used for the 20 common amino acids.

Arg:	-4.5	Ser:	-0.8	Lys:	-3.9
Thr:	-0.7	Asn:	-3.5	Gly:	-0.4
Asp:	-3.5	Ala:	1.8	Gln:	-3.5
Met:	1.9	Glu:	-3.5	Cys:	2.5
His:	-3.2	Phe:	2.8	Pro:	-1.6
Leu:	3.8	Tyr:	-1.3	Val:	4.2
Trp:	-0.9	Ile:	4.5		

[0051] A composition that is “labeled” is detectable, either directly or indirectly, by spectroscopic, photochemical, biochemical, immunochemical, isotopic, or chemical methods. For example, useful labels include ^{32}P , ^{33}P , ^{35}S , ^{14}C , ^3H , ^{125}I , stable isotopes, epitope tags, fluorescent dyes, electron-dense reagents, substrates, or enzymes, e.g., as used in enzyme-linked immunoassays, or fluorettes (see, e.g., Rozinov and Nolan (1998) Chem. Biol. 5:713-728).

[0052] “Ligand” refers to a small molecule, peptide, polypeptide, or membrane associated or membrane-bound molecule, that is an agonist or antagonist of a receptor.

“Ligand” also encompasses a binding agent that is not an agonist or antagonist, and has no agonist or antagonist properties. By convention, where a ligand is membrane-bound on a first cell, the receptor usually occurs on a second cell. The second cell may have the same identity (the same name), or it may have a different identity (a different name), as the first cell. A ligand or receptor may be entirely intracellular, that is, it may reside in the cytosol, nucleus, or in some other intracellular compartment. The ligand or receptor may change its location, e.g., from an intracellular compartment to the outer face of the plasma membrane. The complex of a ligand and receptor is termed a “ligand receptor complex.” Where a ligand and receptor are involved in a signaling pathway, the ligand occurs at an upstream position and the receptor occurs at a downstream position of the signaling pathway.

[0053] “Nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single stranded, double-stranded form, or multi-stranded form. Non-limiting examples of a nucleic acid are a, e.g., cDNA, mRNA, oligonucleotide, and polynucleotide. A particular nucleic acid sequence can also implicitly encompass “allelic variants” and “splice variants.”

[0054] “Operably linked” in the context of a promoter and a nucleic acid encoding a mRNA means that the promoter can be used to initiate transcription of that nucleic acid.

[0055] The terms “percent sequence identity” and “% sequence identity” refer to the percentage of sequence similarity found by a comparison or alignment of two or more amino acid or nucleic acid sequences. Percent identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100. An algorithm for calculating percent identity is the Smith-Waterman homology search algorithm (see, e.g., Kann and Goldstein (2002) *Proteins* 48:367-376; Arslan, et al. (2001) *Bioinformatics* 17:327-337).

[0056] By “purified” and “isolated” is meant, when referring to a polypeptide, that the polypeptide is present in the substantial absence of the other biological macromolecules with which it is associated in nature. The term “purified” as used herein means that an identified polypeptide often accounts for at least 50%, more often accounts for at least

60%, typically accounts for at least 70%, more typically accounts for at least 75%, most typically accounts for at least 80%, usually accounts for at least 85%, more usually accounts for at least 90%, most usually accounts for at least 95%, and conventionally accounts for at least 98% by weight, or greater, of the polypeptides present. The weights of water, buffers, salts, detergents, reductants, protease inhibitors, stabilizers (including an added protein such as albumin), and excipients, and molecules having a molecular weight of less than 1000, are generally not used in the determination of polypeptide purity. See, e.g., discussion of purity in U.S. Pat. No. 6,090,611 issued to Covacci, *et al.*

[0057] “Peptide” refers to a short sequence of amino acids, where the amino acids are connected to each other by peptide bonds. A peptide may occur free or bound to another moiety, such as a macromolecule, lipid, oligo- or polysaccharide, and/or a polypeptide. Where a peptide is incorporated into a polypeptide chain, the term “peptide” may still be used to refer specifically to the short sequence of amino acids. A “peptide” may be connected to another moiety by way of a peptide bond or some other type of linkage. A peptide is at least two amino acids in length and generally less than about 25 amino acids in length, where the maximal length is a function of custom or context. The terms “peptide” and “oligopeptide” may be used interchangeably.

[0058] “Protein” generally refers to the sequence of amino acids comprising a polypeptide chain. Protein may also refer to a three dimensional structure of the polypeptide. “Denatured protein” refers to a partially denatured polypeptide, having some residual three dimensional structure or, alternatively, to an essentially random three dimensional structure, i.e., totally denatured. The invention encompasses reagents of, and methods using, polypeptide variants, e.g., involving glycosylation, phosphorylation, sulfation, disulfide bond formation, deamidation, isomerization, cleavage points in signal or leader sequence processing, covalent and non-covalently bound cofactors, oxidized variants, and the like. The formation of disulfide linked proteins is described (see, e.g., Woycechowsky and Raines (2000) *Curr. Opin. Chem. Biol.* 4:533-539; Creighton, *et al.* (1995) *Trends Biotechnol.* 13:18-23).

[0059] “Recombinant” when used with reference, e.g., to a nucleic acid, cell, animal, virus, plasmid, vector, or the like, indicates modification by the introduction of an exogenous, non-native nucleic acid, alteration of a native nucleic acid, or by derivation in whole or in part from a recombinant nucleic acid, cell, virus, plasmid, or vector.

Recombinant protein refers to a protein derived, e.g., from a recombinant nucleic acid, virus, plasmid, vector, or the like. “Recombinant bacterium” encompasses a bacterium where the genome is engineered by recombinant methods, e.g., by way of a mutation, deletion, insertion, and/or a rearrangement. “Recombinant bacterium” also encompasses a bacterium modified to include a recombinant extra-genomic nucleic acid, e.g., a plasmid or a second chromosome, or a bacterium where an existing extra-genomic nucleic acid is altered.

[0060] “Sample” refers to a sample from a human, animal, placebo, or research sample, e.g., a cell, tissue, organ, fluid, gas, aerosol, slurry, colloid, or coagulated material. The “sample” may be tested *in vivo*, e.g., without removal from the human or animal, or it may be tested *in vitro*. The sample may be tested after processing, e.g., by histological methods. “Sample” also refers, e.g., to a cell comprising a fluid or tissue sample or a cell separated from a fluid or tissue sample. “Sample” may also refer to a cell, tissue, organ, or fluid that is freshly taken from a human or animal, or to a cell, tissue, organ, or fluid that is processed or stored.

[0061] A “selectable marker” encompasses a nucleic acid that allows one to select for or against a cell that contains the selectable marker. Examples of selectable markers include, without limitation, e.g.: (1) A nucleic acid encoding a product providing resistance to an otherwise toxic compound (e.g., an antibiotic), or encoding susceptibility to an otherwise harmless compound (e.g., sucrose); (2) A nucleic acid encoding a product that is otherwise lacking in the recipient cell (e.g., tRNA genes, auxotrophic markers); (3) A nucleic acid encoding a product that suppresses an activity of a gene product; (4) A nucleic acid that encodes a product that can be readily identified (e.g., phenotypic markers such as beta-galactosidase, green fluorescent protein (GFP), cell surface proteins, an epitope tag, a FLAG tag); (5) A nucleic acid that can be identified by hybridization techniques, for example, PCR or molecular beacons.

[0062] “Specifically” or “selectively” binds, when referring to a ligand/receptor, nucleic acid/complementary nucleic acid, antibody/antigen, or other binding pair (e.g., a cytokine to a cytokine receptor) indicates a binding reaction which is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated conditions, a specified ligand binds to a particular receptor and does not bind in a significant amount to other proteins present in the sample. Specific

binding can also mean, e.g., that the binding compound, nucleic acid ligand, antibody, or binding composition derived from the antigen-binding site of an antibody, of the contemplated method binds to its target with an affinity that is often at least 25% greater, more often at least 50% greater, most often at least 100% (2-fold) greater, normally at least ten times greater, more normally at least 20-times greater, and most normally at least 100-times greater than the affinity with any other binding compound.

[0063] In a typical embodiment an antibody will have an affinity that is greater than about 10^9 liters/mol, as determined, e.g., by Scatchard analysis (Munsen, *et al.* (1980) *Analyt. Biochem.* 107:220-239). It is recognized by the skilled artisan that some binding compounds can specifically bind to more than one target, e.g., an antibody specifically binds to its antigen, to lectins by way of the antibody's oligosaccharide, and/or to an Fc receptor by way of the antibody's Fc region.

[0064] "Spread" of a bacterium encompasses "cell to cell spread," that is, transmission of the bacterium from a first host cell to a second host cell, as mediated, for example, by a vesicle. Functions relating to spread include, but are not limited to, e.g., formation of an actin tail, formation of a pseudopod-like extension, and formation of a double-membraned vacuole.

[0065] The term "subject" as used herein refers to a human or non-human organism. Thus, the methods and compositions described herein are applicable to both human and veterinary disease. In certain embodiments, subjects are "patients," i.e., living humans that are receiving medical care for a disease or condition. This includes persons with no defined illness who are being investigated for signs of pathology. Preferred are subjects who have malignancy expressing EGFRvIII. In certain embodiments, the subject is suffering from a glioma (e.g., a GBM), a squamous cell carcinoma of the head and neck, a colorectal cancer, or a breast cancer.

[0066] The "target site" of a recombinase is the nucleic acid sequence or region that is recognized, bound, and/or acted upon by the recombinase (see, e.g., U.S. Pat. No. 6,379,943 issued to Graham, et al.; Smith and Thorpe (2002) *Mol. Microbiol.* 44:299-307; Groth and Calos (2004) *J. Mol. Biol.* 335:667-678; Nunes-Duby, et al. (1998) *Nucleic Acids Res.* 26:391-406).

[0067] “Therapeutically effective amount” is defined as an amount of a reagent or pharmaceutical composition that is sufficient to show a patient benefit, i.e., to cause a decrease, prevention, or amelioration of the symptoms of the condition being treated. When the agent or pharmaceutical composition comprises a diagnostic agent, a “diagnostically effective amount” is defined as an amount that is sufficient to produce a signal, image, or other diagnostic parameter. Effective amounts of the pharmaceutical formulation will vary according to factors such as the degree of susceptibility of the individual, the age, gender, and weight of the individual, and idiosyncratic responses of the individual (see, e.g., U.S. Pat. No. 5,888,530 issued to Netti, *et al.*).

[0068] “Treatment” or “treating” (with respect to a condition or a disease) is an approach for obtaining beneficial or desired results including and preferably clinical results. For purposes of this invention, beneficial or desired results with respect to a disease include, but are not limited to, one or more of the following: improving a condition associated with a disease, curing a disease, lessening severity of a disease, delaying progression of a disease, alleviating one or more symptoms associated with a disease, increasing the quality of life of one suffering from a disease, and/or prolonging survival. Likewise, for purposes of this invention, beneficial or desired results with respect to a condition include, but are not limited to, one or more of the following: improving a condition, curing a condition, lessening severity of a condition, delaying progression of a condition, alleviating one or more symptoms associated with a condition, increasing the quality of life of one suffering from a condition, and/or prolonging survival.

[0069] “Vaccine” encompasses preventative vaccines. Vaccine also encompasses therapeutic vaccines, e.g., a vaccine administered to a mammal that comprises a condition or disorder associated with the antigen or epitope provided by the vaccine.

[0070] 2. Exemplary EGFRvIII Antigens

[0071] The EGFRvIII antigen can comprise a sequence encoding at least one MHC class I epitope and/or at least one MHC class II epitope. The predictive algorithm “BIMAS” ranks potential HLA binding epitopes according to the predictive half-time disassociation of peptide/HLA complexes. The “SYFPEITHI” algorithm ranks peptides according to a score that accounts for the presence of primary and secondary HLA-

binding anchor residues. Both computerized algorithms score candidate epitopes based on amino acid sequences within a given protein that have similar binding motifs to previously published HLA binding epitopes. Other algorithms can also be used to identify candidates for further biological testing.

[0072] As noted above, the EGFRvIII antigenic peptides of the present invention comprise a plurality (2, 3, 4, 5, or more copies) of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3). This sequence represents an H2-Kk-restricted epitope. A preferred EGFRvIII sequence comprises a plurality of copies of the sequence PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 4), referred to herein as EGFRvIII₂₀₋₄₀. This 21-AA sequence overlaps the novel junction created by the 267-AA deletion relative to native EGFR. This also increases the chance of finding a class I-binding epitope that includes the novel glycine at the EGFRvIII splice site (45 unique 7 to 11-AA neo-peptides within EGFRvIII₂₀₋₄₀ versus 22 potential class I-binding peptides in PEPvIII), while not including excessive amounts of native EGFR sequence. In addition, this expanded EGFRvIII peptide increases the number of potential class II-binding epitopes (30 neo-peptides >9-AA in EGFRvIII₂₀₋₄₀ versus 11 in PEPvIII) although vaccine potency is not necessarily dependent upon the presence of EGFRvIII-specific class II restricted epitopes.

[0073] As described hereinafter, antigen dosage is a critical determinate of vaccine potency. In order to maximize the number of EGFRvIII peptide-MHC complexes after vaccination, it is preferred that at least 5 copies of the EGFRvIII polypeptide sequence be included in a single protein construct, with each copy separated by a sequence predicted to facilitate proteasomal cleavage. As one example, such an amino acid sequence may be ASKVLPASRALEEKKGNYVVTDHGSCADGSVKTSASKVAPASRALEEKKGNYVVTDHGSCGDGSIKLSKVLPASRALEEKKGNYVVTDHGSCADGSVKASKVAPASRALEEKKGNYVVTDHGSCGDGSIKLSKVLPASRALEEKKGNYVVTDHGSCADGSVKTS (SEQ ID NO: 15). For the sake of clarity, in this sequence the exemplary EGFRvIII-derived polypeptide sequences are underlined, and the exemplary “cleavable” sequences are not underlined.

[0074] By “immunogenic” as that term is used herein is meant that the antigen is capable of eliciting an antigen-specific humoral or T-cell response (CD4+ and/or CD8+). Selection of one or more antigens or derivatives thereof for use in the vaccine

compositions of the present invention may be performed in a variety of ways, including an assessment of the ability of a bacterium of choice to successfully express and secrete the recombinant antigen(s); and/or the ability of the recombinant antigen(s) to initiate an antigen specific CD4+ and/or CD8+ T cell response. As discussed hereinafter, in order to arrive at a final selection of antigen(s) for use with a particular bacterial delivery vehicle, these attributes of the recombinant antigen(s) are preferably combined with the ability of the complete vaccine platform (meaning the selected bacterial expression system for the selected antigen(s)) to initiate both the innate immune response as well as an antigen-specific T cell response against the recombinantly expressed antigen(s). An initial determination of suitable antigens may be made by selecting antigen(s) or antigen fragment(s) that are successfully recombinantly expressed by the bacterial host of choice (e.g., *Listeria*), and that are immunogenic.

[0075] Direct detection of expression of the recombinant antigen by Western blot may be performed using an antibody that detects the antigenic sequence being recombinantly produced, or using an antibody that detects an included sequence (a “tag”) which is expressed with the EGFRvIII-derived antigen as a fusion protein. For example, the antigen(s) may be expressed as fusions with an N-terminal portion of the *Listeria* ActA protein, and an anti-ActA antibody raised against a synthetic peptide (ATDSEDSSLNTDEWEEK (SEQ ID NO:27)) corresponding to the mature N terminal 18 amino acids of ActA can be used to detect the expressed protein product.

[0076] Assays for testing the immunogenicity of antigens are described herein and are well known in the art. As an example, an antigen recombinantly produced by a bacterium of choice can be optionally constructed to contain the nucleotide sequence encoding an eight amino SIINFEKL (SEQ ID NO:28) peptide (also known as SL8 and ovalbumin₂₅₇₋₂₆₄), positioned in-frame at the carboxyl terminus of the antigen. Compositions such as the C-terminal SL8 epitope serve as a surrogate (i) to demonstrate that the recombinant antigen is being expressed in its entirety from N-terminal to C-terminal, and (ii) to demonstrate the ability of antigen presenting cells to present the recombinant antigen via the MHC class I pathway, using an in vitro antigen presentation assay. Such a presentation assay can be performed using the cloned C57BL/6-derived dendritic cell line DC2.4 together with the B3Z T cell hybridoma cell line as described hereinafter.

[0077] Alternatively, or in addition, immunogenicity may be tested using an ELISPOT assay as described hereinafter. ELISPOT assays were originally developed to enumerate B cells secreting antigen-specific antibodies, but have subsequently been adapted for various tasks, especially the identification and enumeration of cytokine-producing cells at the single cell level. Splensens may be harvested from animals inoculated with an appropriate bacterial vaccine, and the isolated splenocytes incubated overnight with or without peptides derived from the one or more EGFRvIII antigens expressed by the bacterial vaccine. An immobilized antibody captures any secreted IFN- γ , thus permitting subsequent measurement of secreted IFN- γ , and assessment of the immune response to the vaccine.

[0078] 3. Recombinant expression systems – the “vaccine platform”

[0079] Selection of a vaccine platform for delivery of antigens is a critical component for an effective vaccine. Recombinant vectors are prepared using standard techniques known in the art, and contain suitable control elements operably linked to the nucleotide sequence encoding the target antigen. See, for example, Plotkin, *et al.* (eds.) (2003) *Vaccines*, 4th ed., W.B. Saunders, Co., Phila., PA.; Sikora, *et al.* (eds.) (1996) *Tumor Immunology* Cambridge University Press, Cambridge, UK; Hackett and Harn (eds.) *Vaccine Adjuvants*, Humana Press, Totowa, NJ; Isaacson (eds.) (1992) *Recombinant DNA Vaccines*, Marcel Dekker, NY, NY; Morse, *et al.* (eds.) (2004) *Handbook of Cancer Vaccines*, Humana Press, Totowa, NJ, Liao, *et al.* (2005) *Cancer Res.* 65:9089-9098; Dean (2005) *Expert Opin. Drug Deliv.* 2:227-236; Arlen, *et al.* (2003) *Expert Rev. Vaccines* 2:483-493; Dela Cruz, *et al.* (2003) *Vaccine* 21:1317-1326; Johansen, *et al.* (2000) *Eur. J. Pharm. Biopharm.* 50:413-417; Excler (1998) *Vaccine* 16:1439-1443; Disis, *et al.* (1996) *J. Immunol.* 156:3151-3158). Peptide vaccines are described (see, e.g., McCabe, *et al.* (1995) *Cancer Res.* 55:1741-1747; Minev, *et al.* (1994) *Cancer Res.* 54:4155-4161; Snyder, *et al.* (2004) *J. Virology* 78:7052-7060.

[0080] Suitable virus-derived antigen delivery vectors include viruses, modified viruses, and viral particles. The virus-derived vectors can be administered directly to a mammalian subject, or can be introduced *ex vivo* into an antigen presenting cell (APC), where the APC is then administered to the subject. Viral vectors may be based on, e.g., Togaviruses, including alphaviruses and flaviviruses; alphaviruses, such as Sindbis virus, Sindbis strain SAAR86, Semliki Forest virus (SFV), Venezuelan equine encephalitis

(VEE), Eastern equine encephalitis (EEE), Western equine encephalitis, Ross River virus, Sagiya virus, O’Nyong-nyong virus, Highlands J virus. Flaviviruses, such as Yellow fever virus, Yellow fever strain 17D, Japanese encephalitis, St. Louis encephalitis, Tick-borne encephalitis, Dengue virus, West Nile virus, Kunjin virus (subtype of West Nile virus); arterivirus such as equine arteritis virus; and rubivirus such as rubella virus, herpesvirus, modified vaccinia Ankara (MVA); avipox viral vector; fowlpox vector; vaccinia virus vector; influenza virus vector; adenoviral vector, human papilloma virus vector; bovine papilloma virus vector, and so on. Viral vectors may be based on an orthopoxvirus such as variola virus (smallpox), vaccinia virus (vaccine for smallpox), Ankara (MVA), or Copenhagen strain, camelpox, monkeypox, or cowpox. Viral vectors may be based on an avipoxvirus virus, such as fowlpox virus or canarypox virus.

[0081] Adenoviral vectors and adeno-associated virus vectors (AAV) are available, where adenoviral vectors include adenovirus serotype 5 (adeno5; Ad5), adeno6, adeno11, and adeno35. Available are at least 51 human adenovirus serotypes, classified into six subgroups (subgroups A, B, C, D, E, and F). Adenovirus proteins useful, for example, in assessing immune response to an “empty” adenoviral vector, include hexon protein, such as hexon 3 protein, fiber protein, and penton base proteins, and human immune responses to adenoviral proteins have been described (see, e.g., Wu, *et al.* (2002) *J. Virol.* 76:12775-12782; Mascola (2006) *Nature* 441:161-162; Roberts, *et al.* (2006) *Nature* 441:239-243). The following table describes exemplary virus-derived vaccine vectors for use in the present invention:

Adenoviral vectors and adeno-associated virus vectors (AAV).	Polo and Dubensky (2002) <i>Drug Discovery Today</i> 7:719-727; Xin, <i>et al.</i> (2005) <i>Gene Ther.</i> 12:1769-1777; Morenweiser (2005) <i>Gene Ther.</i> 12 (Suppl. 1) S103-S110; Casimiro, <i>et al.</i> (2005) <i>J. Virol.</i> 79:15547-15555; Ferreira, <i>et al.</i> (2005) <i>Gene Ther.</i> 12 Suppl. 1:S73-S83; Baez-Astua, <i>et al.</i> (2005) <i>J. Virol.</i> 79:12807-12817; Vanniasinkam and Ertl (2005) <i>Curr. Gene Ther.</i> 5:203-212; Tatsis and Ertl (2004) <i>Mol. Ther.</i> 10:616-629; Santosuosso, <i>et al.</i> (2005) <i>Viral Immunol.</i> 18:283-291; Zhou, <i>et al.</i> (1996) <i>J. Virol.</i> 70:7030-7038; Zhou, <i>et al.</i> (2002) <i>J. Gene Med.</i> 4:498-509.
Vaccinia virus	Kim, <i>et al.</i> (2005) <i>Hum. Gen. Ther.</i> 16:26-34; Kaufman, <i>et al.</i> (2005) <i>J. Clin. Invest.</i> 115:1903-1912; Kaufman, <i>et al.</i> (2004) <i>J. Clin. Oncol.</i>

	22:2122-2132; Marshall, <i>et al.</i> (2005) <i>J. Clin. Invest.</i> 23:720-731; Hwang and Sanda (1999) <i>Curr. Opin. Mol. Ther.</i> 1:471-479; Baldwin, <i>et al.</i> (2003) <i>Clin. Cancer Res.</i> 9:5205-5213;
Modified vaccinia Ankara (MVA)	Mackova, <i>et al.</i> (2006) <i>Cancer Immunol. Immunother.</i> 55:39-46; Meyer, <i>et al.</i> (2005) <i>Cancer Immunol. Immunother.</i> 54:453-467; Palmowski, <i>et al.</i> (2002) <i>J. Immunol.</i> 168:4391-4398;
Vaccinia derivative NYVAC	Paoletti (1996) <i>Proc. Natl. Acad. Sci. USA</i> 93:11349-11353;
Poxviruses, including avipox, e.g., fowlpox and canarypox	Kaufman (2005) <i>J. Clin. Oncol.</i> 23:659-661; Kudo-Saito, <i>et al.</i> (2004) <i>Clin. Cancer Res.</i> 10:1090-1099; Greiner, <i>et al.</i> (2002) <i>Cancer Res.</i> 62:6944-6951; Marshall, <i>et al.</i> (2005) <i>J. Clin. Invest.</i> 23:720-731; Hwang and Sanda (1999) <i>Curr. Opin. Mol. Ther.</i> 1:471-479; Hodge, <i>et al.</i> (1997) <i>Vaccine</i> 15:759-768; Skinner, <i>et al.</i> (2005) <i>Expert Rev. Vaccines</i> 4:63-76; Rosenberg, <i>et al.</i> (2003) <i>Clin. Cancer Res.</i> 9:2973-2980.
Antigen presenting cells transduced with a virus-derived vector.	Di Nicola, <i>et al.</i> (2004) <i>Clin. Cancer Res.</i> 10:5381-5390;
Alphavirus-derived vectors, e.g., Sindbis virus, Semliki Forest virus, and Venezuelan equine encephalitis (VEE).	Polo and Dubensky (2002) <i>Drug Discovery Today</i> 7:719-727; Polo, <i>et al.</i> (1999) <i>Proc. Natl. Acad. Sci. USA</i> 96:4598-4603; Schlesinger (2001) <i>Expert Opin. Biol. Ther.</i> 1:177-191; Pan, <i>et al.</i> (2005) <i>Proc. Natl. Acad. Sci. USA</i> 102:11581-11588; Lundstrom (2003) <i>Expert Rev. Vaccines</i> 2:447-459; Shafferman, <i>et al.</i> (1996) <i>Adv. Exp. Med. Biol.</i> 397:41-47; Yamanaka (2004) <i>Int. J. Oncol.</i> 24:919-923; Atkins, <i>et al.</i> (2004) <i>Curr. Cancer Drug Targets</i> 4:597-607.
Chimeric virus-derived vectors, such as chimeric alphaviruses.	Sindbis virus/Venezuelan equine encephalitis virus (SINV/VEEV) (see, e.g., Perri, <i>et al.</i> (2003) <i>J. Virol.</i> 77:10394-10403; Paessler, <i>et al.</i> (2003) <i>J. Virol.</i> 77:9278-9286).
Herpesviruses, including herpes simplex and	Hellebrand, <i>et al.</i> (2006) <i>Gene Ther.</i> 13:150-162; Lauterbach, <i>et al.</i> (2005) <i>J. Gen. Virol.</i> 86:2401-2410; Zibert, <i>et al.</i> (2005) <i>Gene Ther.</i> 12:1707-1717; Thiry, <i>et al.</i> (2006) <i>Vet. Microbiol.</i> 113:171-177;

Epstein-Barr virus-derived vectors	Trapp, <i>et al.</i> (2005) <i>J. Virol.</i> 79:5445-5454.
Rhinoviruses	Dollenmaier, <i>et al.</i> (2001) <i>Virology</i> 281:216-230; Arnold, <i>et al.</i> (1996) <i>Intervirology</i> 39:72-78.
Lentiviruses	DePolo, <i>et al.</i> (2000) <i>Mol. Ther.</i> 2:218-222; Pellinen, <i>et al.</i> (2004) <i>Int. J. Oncol.</i> 25:1753-1762; Esslinger, <i>et al.</i> (2003) <i>J. Clin. Invest.</i> 111:1673-1681; Kikuchi, <i>et al.</i> (2004) <i>Clin. Cancer Res.</i> 10:1835-1842; Kim, <i>et al.</i> (2005) <i>Hum. Gene Ther.</i> 16:1255-1266.
Viral particle vaccines	Polo and Dubensky (2002) <i>Drug Discovery Today</i> 7:719-727; Cheng, <i>et al.</i> (2002) <i>Hum. Gene Ther.</i> 13:553-568; Lin, <i>et al.</i> (2003) <i>Mol. Ther.</i> 8:559-566; Balasuriya, <i>et al.</i> (2000) <i>J. Virol.</i> 74:10623-10630; Goldberg, <i>et al.</i> (2005) <i>Clin. Cancer Res.</i> 11:8114-8121; Johnston, <i>et al.</i> (2005) <i>Vaccine</i> 23:4969-4979; Quinnan, <i>et al.</i> (2005) <i>J. Virol.</i> 79:3358-3369; Casseti, <i>et al.</i> (2004) <i>Vaccine</i> 22:520-527; Williamson, <i>et al.</i> (2003) <i>AIDS Res. Hum. Retroviruses</i> 19:133-144; Perri, <i>et al.</i> (2003) <i>J. Virol.</i> 77:10394-10403; Da Silva, <i>et al.</i> (2003) <i>Vaccine</i> 21:3219-3227;

[0082] Antigen presenting cell (APC) vectors, such as a dendritic cell (DC) vector, include cells that are loaded with an antigen, loaded with a tumor lysate, or transfected with a composition comprising a nucleic acid, where the nucleic acid can be, e.g., a plasmid, mRNA, or virus. DC/tumor fusion vaccines may also be used. See, e.g., Di Nicola, *et al.* (2004) *Clin. Cancer Res.* 10:5381-5390; Cerundolo, *et al.* (2004) *Nature Immunol.* 5:7-10; Parmiani, *et al.* (2002) *J. Natl. Cancer Inst.* 94:805-818; Kao, *et al.* (2005) *Immunol. Lett.* 101:154-159; Geiger, *et al.* (2005) *J. Transl. Med.* 3:29; Osada, *et al.* (2005) *Cancer Immunol. Immunother.* Nov.5,1-10 [epub ahead of print]; Malowany, *et al.* (2005) *Mol. Ther.* 13:766-775; Morse and Lyerly (2002) *World J. Surg.* 26:819-825; Gabilovich (2002) *Curr. Opin. Mol. Ther.* 4:454-458; Morse, *et al.* (2003) *Clin. Breast Cancer* 3 Suppl.4:S164-S172; Morse, *et al.* (2002) *Cancer Chemother. Biol. Response Modif.* 20:385-390; Arlen, *et al.* (2003) *Expert Rev. Vaccines* 2:483-493; Morse and Lyerly (1998) *Expert Opin. Investig. Drugs* 7:1617-1627; Hirschowitz, *et al.*

(2004) *J. Clin. Oncol.* 22:2808-2815; Vasir, *et al.* (2005) *Br. J. Haematol.* 129:687-700; Koido, *et al.* (2005) *Gynecol. Oncol.* 99:462-471.

[0083] Tumor cells, for example, autologous and allogeneic tumor cells, are available as vaccines (Arlen, *et al.* (2005) *Semin. Oncol.* 32:549-555). A vaccine may also comprise a modified tumor cell, for example, a tumor cell lysate, or an irradiated tumor cell. The tumor cell can also be modified by incorporating a nucleic acid encoding an molecule such as a cytokine (GM-CSF, IL-12, IL-15, and the like), a NKG2D ligand, CD40L, CD80, CD86, and the like (see, e.g., Dranoff (2002) *Immunol. Rev.* 188:147-154; Jain, *et al.* (2003) *Ann. Surg. Oncol.* 10:810-820; Borrello and Pardoll (2002) *Cytokine Growth Factor Rev.* 13:185-193; Chen, *et al.* (2005) *Cancer Immunol. Immunother.* 27:1-11; Kjaergaard, *et al.* (2005) *J. Neurosurg.* 103:156-164; Tai, *et al.* (2004) *J. Biomed. Sci.* 11:228-238; Schwaab, *et al.* (2004) *J. Urol.* 171:1036-1042; Friese, *et al.* (2003) *Cancer Res.* 63:8996-9006; Briones, *et al.* (2002) *Cancer Res.* 62:3195-3199; Vieweg and Dannull (2003) *Urol. Clin. North Am.* 30:633-643; Mincheff, *et al.* (2001) *Crit. Rev. Oncol. Hematol.* 39:125-132).

[0084] Antigen expression platforms may also be provided using naked DNA vectors and naked RNA vectors. These vaccines containing nucleic acids may be administered by a gene gun, electroporation, bacterial ghosts, microspheres, microparticles, liposomes, polycationic nanoparticles, and the like (see, e.g., Donnelly, *et al.* (1997) *Ann. Rev. Immunol.* 15:617-648; Mincheff, *et al.* (2001) *Crit. Rev. Oncol. Hematol.* 39:125-132; Song, *et al.* (2005) *J. Virol.* 79:9854-9861; Estcourt, *et al.* (2004) *Immunol. Rev.* 199:144-155). Reagents and methodologies for administration of naked nucleic acids, e.g., by way of a gene gun, intradermic, intramuscular, and electroporation methods, are available. The nucleic acid vaccines may comprise a locked nucleic acid (LNA), where the LNA allows for attachment of a functional moiety to the plasmid DNA, and where the functional moiety can be an adjuvant (see, e.g., Fensterle, *et al.* (1999) *J. Immunol.* 163:4510-4518; Strugnell, *et al.* (1997) *Immunol. Cell Biol.* 75:364-369; Hertoughs, *et al.* (2003) *Nucleic Acids Res.* 31:5817-5830; Trimble, *et al.* (2003) *Vaccine* 21:4036-4042; Nishitani, *et al.* (2000) *Mol. Urol.* 4:47-50; Tuting (1999) *Curr. Opin. Mol. Ther.* 1:216-225). Nucleic acid vaccines can be used in combination with reagents that promote migration of immature dendritic cells towards the vaccine, and a reagent that promotes migration of mature DCs to the draining lymph node where priming can occur, where

these reagents encompass MIP-1alpha and Flt3L (see, e.g., Kutzler and Weiner (2004) J. Clin. Invest. 114:1241-1244; Sumida, *et al.* (2004) J. Clin. Invest. 114:1334-1342).

[0085] A number of bacterial species have been developed for use as vaccines and can be used in the present invention, including, but not limited to, *Shigella flexneri*, *Escherichia coli*, *Listeria monocytogenes*, *Yersinia enterocolitica*, *Salmonella typhimurium*, *Salmonella typhi* or *mycobacterium species*. This list is not meant to be limiting. See, e.g., WO04/006837; WO07/103225; and WO07/117371, each of which is hereby incorporated by reference in its entirety, including all tables, figures, and claims. The bacterial vector used in the vaccine composition may be a facultative, intracellular bacterial vector. The bacterium may be used to deliver a polypeptide described herein to antigen-presenting cells in the host organism. As described herein, *L. monocytogenes* provides a preferred vaccine platform for expression of the antigens of the present invention.

[0086] Both attenuated and commensal microorganisms have been successfully used as carriers for vaccine antigens, but bacterial carriers for the antigens are optionally attenuated or killed but metabolically active (KBMA). The genetic background of the carrier strain used in the formulation, the type of mutation selected to achieve attenuation, and the intrinsic properties of the immunogen can be adjusted to optimize the extent and quality of the immune response elicited. The general factors to be considered to optimize the immune response stimulated by the bacterial carrier include: selection of the carrier; the specific background strain, the attenuating mutation and the level of attenuation; the stabilization of the attenuated phenotype and the establishment of the optimal dosage. Other antigen-related factors to consider include: intrinsic properties of the antigen; the expression system, antigen-display form and stabilization of the recombinant phenotype; co-expression of modulating molecules and vaccination schedules.

[0087] A preferred feature of the vaccine platform is the ability to initiate both the innate immune response as well as an antigen-specific T cell response against the recombinantly expressed antigen(s). For example, *L. monocytogenes* expressing the antigen(s) described herein can induce intrahepatic Type 1 interferon (IFN- α/β) and a downstream cascade of chemokines and cytokines. In response to this intrahepatic immune stimulation, NK cells and antigen presenting cells (APCs) are recruited to the liver. In certain embodiments, the vaccine platform of the present invention induces an

increase at 24 hours following delivery of the vaccine platform to the subject in the serum concentration of one or more, and preferably all, cytokines and chemokines selected from the group consisting of IL-12p70, IFN- γ , IL-6, TNF α , and MCP-1; and induces a CD4+ and/or CD8+ antigen-specific T cell response against one or more EGFRvIII-derived antigens expressed by the vaccine platform. In other embodiments, the vaccine platform of the present invention also induces the maturation of resident immature liver NK cells as demonstrated by the upregulation of activation markers such as DX5, CD11b, and CD43 in a mouse model system, or by NK cell-mediated cytolytic activity measured using ^{51}Cr -labeled YAC-1 cells that were used as target cells.

[0088] In various embodiments, the vaccines and immunogenic compositions of the present invention can comprise *Listeria monocytogenes* configured to express the desired EGFRvIII-derived antigen(s). The ability of *L. monocytogenes* to serve as a vaccine vector has been reviewed in Wesikirch, *et al.*, *Immunol. Rev.* 158:159-169 (1997). A number of desirable features of the natural biology of *L. monocytogenes* make it an attractive platform for application to a therapeutic vaccine. The central rationale is that the intracellular lifecycle of *L. monocytogenes* enables effective stimulation of CD4+ and CD8+ T cell immunity. Multiple pathogen associated molecular pattern (PAMP) receptors including TLRs (TLR2, TLR5, TLR9) and nucleotide-binding oligomerization domains (NOD) are triggered in response to interaction with *L. monocytogenes* macromolecules upon infection, resulting in the pan-activation of innate immune effectors and release of Th-1 polarizing cytokines, exerting a profound impact on the development of a CD4+ and CD8+ T cell response against the expressed antigens.

[0089] Strains of *L. monocytogenes* have recently been developed as effective intracellular delivery vehicles of heterologous proteins providing delivery of antigens to the immune system to induce an immune response to clinical conditions that do not permit injection of the disease-causing agent, such as cancer and HIV. See, e.g., U.S. Pat. No. 6,051,237; Gunn *et al.*, *J. Immunol.*, 167:6471-6479 (2001); Liao, *et al.*, *Cancer Research*, 62: 2287-2293 (2002); U.S. Pat. No. 6,099,848; WO 99/25376; WO 96/14087; and U.S. Pat. No. 5,830,702), each of which is hereby incorporated by reference in its entirety, including all tables, figures, and claims. A recombinant *L. monocytogenes* vaccine expressing an lymphocytic choriomeningitis virus (LCMV) antigen has also been

shown to induce protective cell-mediated immunity to the antigen (Shen et al., Proc. Natl. Acad. Sci. USA, 92: 3987-3991 (1995)).

[0090] Attenuated and killed but metabolically active forms of *L. monocytogenes* useful in immunogenic compositions have been produced. WO07/103225; and WO07/117371), each of which is hereby incorporated by reference in its entirety, including all tables, figures, and claims. The ActA protein of *L. monocytogenes* is sufficient to promote the actin recruitment and polymerization events responsible for intracellular movement. A human safety study has reported that oral administration of an actA/plcB-deleted attenuated form of *L. monocytogenes* caused no serious sequelae in adults (Angelakopoulos *et al.*, *Infection and Immunity*, 70:3592-3601 (2002)). Other types of attenuated forms of *L. monocytogenes* have also been described (see, for example, WO 99/25376 and U.S. Pat. No. 6,099,848, which describe auxotrophic, attenuated strains of *Listeria* that express heterologous antigens).

[0091] In certain embodiments, the *L. monocytogenes* used in the vaccine compositions of the present invention is a live-attenuated strain which comprises an attenuating mutation in actA and/or inlB, and preferably a deletion of all or a portion of actA and inlB (referred to herein as "*Lm* Δ actA/ Δ inlB"), and contains recombinant DNA encoding for the expression of the EGFRvIII-derived antigen(s) of interest. The EGFRvIII-derived antigen(s) are preferably under the control of bacterial expression sequences and are stably integrated into the *L. monocytogenes* genome. Such a *L. monocytogenes* vaccine strain therefore employs no eukaryotic transcriptional or translational elements.

[0092] The invention also contemplates a *Listeria* attenuated in at least one regulatory factor, e.g., a promoter or a transcription factor. The following concerns promoters. ActA expression is regulated by two different promoters (Vazwuez-Boland, et al. (1992) *Infect. Immun.* 60:219-230). Together, InlA and InlB expression is regulated by five promoters (Lingnau, et al. (1995) *Infect. Immun.* 63:3896-3903). The transcription factor prfA is required for transcription of a number of *L. monocytogenes* genes, e.g., *hly*, *plcA*, *ActA*, *mpl*, *prfA*, and *iap*. PrfA's regulatory properties are mediated by, e.g., the PrfA-dependent promoter (*PinlC*) and the *PrfA*-box. The present invention, in certain embodiments, provides a nucleic acid encoding inactivated, mutated, or deleted in at least one of *ActA* promoter, *inlB* promoter, *PrfA*, *PinlC*, *PrfA* box, and the like (see, e.g., Lalic

Mullthaler, et al. (2001) Mol. Microbiol. 42:111-120; Shetron-Rama, et al. (2003) Mol. Microbiol. 48:1537-1551; Luo, et al. (2004) Mol. Microbiol. 52:39-52). PrfA can be made constitutively active by a Gly145Ser mutation, Gly155Ser mutation, or Glu77Lys mutation (see, e.g., Mueller and Freitag (2005) Infect. Immun. 73:1917-1926; Wong and Freitag (2004) J. Bacteriol. 186:6265-6276; Ripio, et al. (1997) J. Bacteriol. 179:1533-1540).

[0093] Attenuation can be effected by, e.g., heat-treatment or chemical modification. Attenuation can also be effected by genetic modification of a nucleic acid that modulates, e.g., metabolism, extracellular growth, or intracellular growth, genetic modification of a nucleic acid encoding a virulence factor, such as *Listerial prfA*, *actA*, listeriolysin (LLO), an adhesion mediating factor (e.g., an internalin such as *inlA* or *inlB*), *mpl*, phosphatidylcholine phospholipase C (PC-PLC), phosphatidylinositol-specific phospholipase C (PI PLC; *plcA* gene), any combination of the above, and the like. Attenuation can be assessed by comparing a biological function of an attenuated *Listeria* with the corresponding biological function shown by an appropriate parent *Listeria*.

[0094] The present invention, in other embodiments, provides a *Listeria* that is attenuated by treating with a nucleic acid targeting agent, such as a cross linking agent, a psoralen, a nitrogen mustard, cis platin, a bulky adduct, ultraviolet light, gamma irradiation, any combination thereof, and the like. Typically, the lesion produced by one molecule of cross linking agent involves cross linking of both strands of the double helix. The *Listeria* of the invention can also be attenuated by mutating at least one nucleic acid repair gene, e.g., *uvrA*, *uvrB*, *uvrAB*, *uvrC*, *uvrD*, *uvrAB*, *phrA*, and/or a gene mediating recombinational repair, e.g., *recA*. Moreover, the invention provides a *Listeria* attenuated by both a nucleic acid targeting agent and by mutating a nucleic acid repair gene. Additionally, the invention encompasses treating with a light sensitive nucleic acid targeting agent, such as a psoralen, and/or a light sensitive nucleic acid cross linking agent, such as psoralen, followed by exposure to ultraviolet light.

[0095] Attenuated *Listeria* useful in the present invention are described in, e.g., in U.S. Pat. Publ. Nos. 2004/0228877 and 2004/0197343, each of which is incorporated by reference herein in its entirety. Various assays for assessing whether a particular strain of *Listeria* has the desired attenuation are provided, e.g., in U.S. Pat. Publ. Nos.

2004/0228877, 2004/0197343, and 2005/0249748, each of which is incorporated by reference herein in its entirety.

[0096] In other embodiments, the *L. monocytogenes* used in the vaccine compositions of the present invention is a killed but metabolically active (KBMA) platform derived from *Lm* $\Delta actA/\Delta inlB$, and also is deleted of both *uvrA* and *uvrB*, genes encoding the DNA repair enzymes of the nucleotide excision repair (NER) pathway, and contains recombinant DNA encoding for the expression of the EGFRvIII-derived antigen(s) of interest. The *antigen(s) of interest* are preferably under the control of bacterial expression sequences and are stably integrated into the *L. monocytogenes* genome. The KBMA platform is exquisitely sensitive to photochemical inactivation by the combined treatment with the synthetic psoralen, S-59, and long-wave UV light. While killed, KBMA *Lm* vaccines can transiently express their gene products, allowing them to escape the phagolysosome and induce functional cellular immunity and protection against wild-type WT *Lm* and vaccinia virus challenge.

[0097] In certain embodiments, an attenuated or KBMA *L. monocytogenes* vaccine strain comprise a constitutively active *prfA* gene (referred to herein as PrfA* mutants). PrfA is a transcription factor activated intracellularly which induces expression of virulence genes and encoded heterologous antigens (Ags) in appropriately engineered vaccine strains. As noted above, expression of the *actA* gene is responsive to PrfA, and the *actA* promoter is a PrfA responsive regulatory element. Inclusion of a *prfA* G155S allele can confer significant enhanced vaccine potency of live-attenuated or KBMA vaccines. Preferred PrfA mutants are described in U.S. Provisional patent application 61/054,454, entitled COMPOSITIONS COMPRISING PRFA* MUTANT *LISTERIA* AND METHODS OF USE THEREOF, filed May 19, 2008, which is hereby incorporated in its entirety including all tables, figures, and claims.

[0098] The sequence of *L. monocytogenes* PrfA, which includes a glycine at residue 155, is as follows (SEQ ID NO: 16):

```
MNAQAEEFKK YLETNGIKPK QFHKKELIFN QWDPQEYCIF LYDGITKLTS 50
ISENGTIMNL QYYKGAFVIM SGFIDTETSV GYYNLEWISE QATAYVIKIN 100
ELKELLSKNL THFFYVFQTL QKQVSYSLAK FNDFSINGKL GSICGQLLIL 150
TYVYGKETPD GIKITLDNLT MQELGYSSGI AHSSAVSRII SKLKQEKVIV 200
```


YKNSCFYVQN LDYLKRYAPK LDEWFYLACP ATWGKLN 237

[0099] The sequence of *L. monocytogenes* PrfA*, which includes a serine at residue 155, is as follows (SEQ ID NO: 17):

MNAQAEEFKK YLETNGIKPK QFHKKELIFN QWDPQEYCF LYDGITKLTS 50
 ISENGTIMNL QYYKGAFVIM SGFIDTETSV GYYNLEWISE QATAYVIKIN 100
 ELKELLSKNL THFFYVFQTL QKQVSYSLAK FNDFSINGKL GSICGQLLIL 150
 TYVYSKETPD GIKITLDNLT MQELGYSSGI AHSSAVSRII SKLKQEKVIV 200
 YKNSCFYVQN LDYLKRYAPK LDEWFYLACP ATWGKLN 237

4. Antigenic constructs

[0100] The antigenic construct expressed by the vaccine strain of the present invention comprises at a minimum a nucleic acid encoding a secretory sequence operable within the vaccine platform to support secretion, fused to the EGFRvIII-derived antigen(s) to be expressed. In the case of a bacterial platform, the resulting fusion protein is operably linked to regulatory sequences (*e.g.*, a promoter) necessary for expression of the fusion protein by the bacterial vaccine platform. The present invention is not to be limited to polypeptide and peptide antigens that are secreted, but also embraces polypeptides and peptides that are not secreted or cannot be secreted from a *Listeria* or other bacterium. But preferably, the EGFRvIII-derived antigen(s) are expressed in a soluble, secreted form by a bacterial vaccine strain when the strain is inoculated into a recipient.

[0101] Table 1 discloses a number of non-limiting examples of signal peptides for use in fusing with a fusion protein partner sequence such as a heterologous antigen. Signal peptides tend to contain three domains: a positively charged N-terminus (1-5 residues long); a central hydrophobic domain (7-15 residues long); and a neutral but polar C-terminal domain.

Table 1. Bacterial signal pathway. Signal peptides are identified by the signal peptidase site.

Signal peptidase site (cleavage site represented by ')	Gene	Genus/species
secA1 pathway		
TEA'KD (SEQ ID NO: 18)	<i>hly</i> (LLO)	<i>Listeria monocytogenes</i>
VYA'DT (SEQ ID NO: 19)	Usp45	<i>Lactococcus lactis</i>
IQA'EV (SEQ ID NO: 20)	<i>pag</i> (protective antigen)	<i>Bacillus anthracis</i>
secA2 pathway		
ASA'ST (SEQ ID NO: 21)	<i>iap</i> (invasion-associated protein) p60	<i>Listeria monocytogenes</i>
VGA'FG (SEQ ID NO: 22)	NamA Imo2691 (autolysin)	<i>Listeria monocytogenes</i>
AFA'ED (SEQ ID NO: 23)	* BA_0281 (NLP/P60 Family)	<i>Bacillus anthracis</i>
VQA'AE (SEQ ID NO: 24)	* <i>atl</i> (autolysin)	<i>Staphylococcus aureus</i>
Tat pathway		
DKA'LT (SEQ ID NO: 25)	Imo0367	<i>Listeria monocytogenes</i>
VGA'FG (SEQ ID NO: 26)	PhoD (alkaline phosphatase)	<i>Bacillus subtilis</i>
<p>* Bacterial autolysins secreted by sec pathway (not determined whether secA1 or secA2). Secretory sequences are encompassed by the indicated nucleic acids encoded by the <i>Listeria</i> EGD genome (GenBank Acc. No. NC_003210) at, e.g., nucleotides 45434-456936 (inIA); nucleotides 457021-457125 (inIB); nucleotides 1860200-1860295 (inIC); nucleotides 286219-287718 (inIE); nucleotides 205819-205893 (<i>hly</i> gene; LLO) (see also GenBank Acc. No. P13128); nucleotides 209470-209556 (<i>ActA</i>) (see also GenBank Acc. No. S20887).</p> <p>The referenced nucleic acid sequences, and corresponding translated amino acid sequences, and the cited amino acid sequences, and the corresponding nucleic acid sequences associated with or cited in that reference, are incorporated by reference herein in their entirety.</p>		

[0102] In certain exemplary embodiments described hereinafter, the EGFRvIII-derived sequence(s) may be expressed as a single polypeptide fused to an amino-terminal portion of the *L. monocytogenes* ActA protein which permits expression and secretion of a fusion protein from the bacterium within the vaccinated host. In these embodiments, the antigenic construct may be a polynucleotide comprising a promoter operably linked to a nucleic acid sequence encoding a fusion protein, wherein the fusion protein comprises (a) modified ActA and (b) one or more EGFRvIII-derived epitopes to be expressed as a fusion protein following the modified ActA sequence.

[0103] By “modified ActA” is meant a contiguous portion of the *L. monocytogenes* ActA protein which comprises at least the ActA signal sequence, but does not comprise the entirety of the ActA sequence, or that has at least about 80 % sequence identity, at least about 85% sequence identity, at least about 90% sequence identity, at least about 95% sequence identity, or at least about 98% sequence identity to such an ActA sequence. The ActA signal sequence is MGLNRFMRAMMVVFITANCITINPDIIFA (SEQ ID NO: 27). In some embodiments, the promoter is *ActA* promoter from WO07/103225; and WO07/117371, each of which is incorporated by reference in its entirety herein.

[0104] By way of example, the modified ActA may comprise at least the first 59 amino acids of ActA, or a sequence having at least about 80 % sequence identity, at least about 85% sequence identity, at least about 90% sequence identity, at least about 95% sequence identity, or at least about 98% sequence identity to at least the first 59 amino acids of ActA. In some embodiments, the modified ActA comprises at least the first 100 amino acids of ActA, or a sequence having at least about 80 % sequence identity, at least about 85% sequence identity, at least about 90% sequence identity, at least about 95% sequence identity, or at least about 98% sequence identity to the first 100 amino acids of ActA. In other words, in some embodiments, the modified ActA sequence corresponds to an N-terminal fragment of ActA (including the ActA signal sequence) that is truncated at residue 100 or thereafter.

[0105] ActA-N100 has the following sequence (SEQ ID NO: 28):

```
VGLNRFMRAM MVVFITANCI TINPDIIFAA TSEDSSLNT DEWEEEEKTEE 50
QPSEVNTGPR YETAREVSSR DIEELEKSNK VKNTNKADLI AMLKAKAEKG 100
```

[0106] In this sequence, the first residue is depicted as a valine; the polypeptide is synthesized by *Listeria* with a methionine in this position. Thus, ActA-N100 may also have the following sequence (SEQ ID NO:29):

```
MGLNRFMRAM MVVFITANCI TINPDIIFAA TSEDSSLNT DEWEEEEKTEE 50
QPSEVNTGPR YETAREVSSR DIEELEKSNK VKNTNKADLI AMLKAKAEKG 100
```

[0107] ActA-N100 may also comprise one or more additional residues lying between the C-terminal residue of the modified ActA and the EGFRvIII-derived antigen sequence. In the following sequences, ActA-N100 is extended by two residues added by inclusion of a BamHI site:

```
VGLNRFMRAM MVVFITANCI TINPDIIFAA TSEDSSLNT DEWEEEEKTEE 50
QPSEVNTGPR YETAREVSSR DIEELEKSNK VKNTNKADLI AMLKAKAEKG 100
```

GS (SEQ ID NO: 30)

which when synthesized with a first residue methionine has the sequence:

```
MGLNRFMRAM MVVFITANCI TINPDIIFAA TSEDSSLNT DEWEEEEKTEE 50
QPSEVNTGPR YETAREVSSR DIEELEKSNK VKNTNKADLI AMLKAKAEKG 100
```

GS (SEQ ID NO: 31).

[0108] Thus, an exemplary construct is as follows:

```
vglnrfrmram mvvfitanci tinpdiifaa tdsedsslnt deweeektee 50
qpsevntgpr yetarevssr dieeleksnk vkntnkadli amlkakaekg 100
gsASKVLPAS RALEEKKGNY VVIDHGSCAD GSVKTSASKV APASRALEEK 150
```

KGNYVVTDHG SCGDGSIKLS KVLPASRALE EKKGNYVVTD HGSCADGSVK 200

ASKVAPASRA LEEKKGNYVV TDHGSCGDGS IKLSKVLPAS RALEEKKGNY 250

VVTDHGSCAD GSVKTS (SEQ ID NO: 32). In this sequence, the ActA-N100 sequence is in lowercase, the EGFRvIII-derived antigen sequences are underlined, and the linker “cleavable” sequences are not underlined. A corresponding DNA sequence is as follows:

gtgggattaaatagatttatgcgtgcgatgatggtagttttcattactgccaaactgcatt
acgattaacccccgacataatatttgcagcgacagatagcgaagattccagctaaacaca
gatgaatgggaagaagaaaaacagaagagcagccaagcgaggtaaatacgggaccaaga
tacgaaactgcacgtgaagtaagttcacgtgatattgaggaactagaaaaatcgaataaa
gtgaaaaatacgaacaaagcagacctaatagcaatggtgaaagcaaaagcagagaaaggt
ggatccGCAAGCAAAGTATTGCCAGCTAGTCGTGCATTAGAGGAGAAAAAGGGGAATTAC
GTGGTGACGGATCATGGATCGTGTGCCGATGGCTCAGTAAAGACTAGTGCGAGCAAAGTG
GCCCCTGCATCACGAGCACTTGAAGAGAAAAAGGAAACTATGTTGTGACCGATCATGGT
AGCTGCGGAGATGGTTCAATTAAATTATCAAAAAGTCTTACCAGCATCTAGAGCTTTAGAG
GAAAAGAAGGGTAACTATGTCGTAACAGATCATGGAAGTTGTGCTGACGGAAGTGTTAAA
GCGTCGAAAGTAGCTCCAGCTTCTCGCGCATTAGAAGAAAAGAAAGGCAATTATGTTGTA
ACAGACCATGGTAGTTGTGGTGATGGCTCGATCAAATTGTCAAAAAGTTCTACCGGCTTCT
CGTGCGCTAGAAGAGAAGAAAGGAAATTACGTAGTTACAGACCACGGCTCTTGCGCGGAT
GGTCCGTTAAACTAGT (SEQ ID NO: 33). In this sequence, the ActA-N100 sequence

is in lowercase, a BamHI cloning site is underlined, and the EGFRvIII-derived antigen and linker “cleavable” sequences are not underlined. This sequence may be preceded by an ActA promoter sequence, such as

gggaagcagttggggtaactgattaacaaatgtagagaaaaattaattctccaagtga
tattcttaaaataattcatgaatattttttcttatattagctaattaagaagataattaa
ctgctaattccaatttttaacggaataaattagtgaaaatgaaggccgaattttccttggt
ctaaaaaggttgtagtagcgtatcacgaggaggagataaa (SEQ ID NO: 34).

[0109] Exemplary constructs are described hereinafter and in WO07/103225, which is incorporated by reference herein. ANZ-100 (formerly known as CRS-100; BB-IND 12884 and clinicaltrials.gov identifier NCT00327652) consists of a *L. monocytogenes* Δ actA/ Δ inlB platform without any exogenous antigen expression sequences. In the exemplary constructs described in WO07/103225, this platform has been engineered to

express human Mesothelin as a fusion with ActA-N100. The mesothelin expression vaccine has been evaluated in subjects with advanced carcinoma with liver metastases using CRS-207 (BB-IND 13389 and clinicaltrials.gov identifier NCT00585845). The present invention contemplates modification of this vaccine by replacing the mesothelin sequences with EGFRvIII-derived antigen sequences.

[0110] As sequences encoded by one organism are not necessarily codon optimized for optimal expression in a chosen vaccine platform bacterial strain, the present invention also provides nucleic acids that are altered by codon optimized for expressing by a bacterium such as *L. monocytogenes*.

[0111] In various embodiments, at least one percent of any non-optimal codons are changed to provide optimal codons, more normally at least five percent are changed, most normally at least ten percent are changed, often at least 20% are changed, more often at least 30% are changed, most often at least 40%, usually at least 50% are changed, more usually at least 60% are changed, most usually at least 70% are changed, optimally at least 80% are changed, more optimally at least 90% are changed, most optimally at least 95% are changed, and conventionally 100% of any non-optimal codons are codon-optimized for *Listeria* expression (Table 2).

Table 2. Optimal codons for expression in *Listeria*.

Amino Acid	A	R	N	D	C	Q	E	G	H	I
Optimal <i>Listeria</i> codon	GCA	CGU	AAU	GAU	UGU	CAA	GAA	GGU	CAU	AUU
Amino Acid	L	K	M	F	P	S	T	W	Y	V
Optimal <i>Listeria</i> codon	UUA	AAA	AUG	UUU	CCA	AGU	ACA	UGG	UAU	GUU

[0112] The invention supplies a number of *Listerial* species and strains for making or engineering a vaccine platform of the present invention. The *Listeria* of the present invention is not to be limited by the species and strains disclosed in Table 3.

Table 3. Strains of *Listeria* suitable for use in the present invention, e.g., as a vaccine or as a source of nucleic acids.

<i>L. monocytogenes</i> 10403S wild type.	Bishop and Hinrichs (1987) J. Immunol. 139:2005-2009; Lauer, <i>et al.</i> (2002) J. Bact. 184:4177-4186.
<i>L. monocytogenes</i> DP-L4056 (phage cured). The prophage-cured 10403S strain is designated DP-L4056.	Lauer, <i>et al.</i> (2002) J. Bact. 184:4177-4186.
<i>L. monocytogenes</i> DP-L4027, which is DP-L2161, phage cured, deleted in hly gene.	Lauer, <i>et al.</i> (2002) J. Bact. 184:4177-4186; Jones and Portnoy (1994) Infect. Immunity 65:5608-5613.
<i>L. monocytogenes</i> DP-L4029, which is DP-L3078, phage cured, deleted in ActA.	Lauer, <i>et al.</i> (2002) J. Bact. 184:4177-4186; Skoble, <i>et al.</i> (2000) J. Cell Biol. 150:527-538.
<i>L. monocytogenes</i> DP-L4042 (delta PEST)	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.
<i>L. monocytogenes</i> DP-L4097 (LLO-S44A).	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.
<i>L. monocytogenes</i> DP-L4364 (delta lplA; lipoate protein ligase).	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.
<i>L. monocytogenes</i> DP-L4405 (delta inlA).	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.
<i>L. monocytogenes</i> DP-L4406 (delta inlB).	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.
<i>L. monocytogenes</i> CS-L0001 (delta ActA-delta inlB).	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.

<i>L. monocytogenes</i> CS-L0002 (delta ActA-delta lplA).	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.
<i>L. monocytogenes</i> CS-L0003 (L461T-delta lplA).	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.
<i>L. monocytogenes</i> DP-L4038 (delta ActA-LLO L461T).	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.
<i>L. monocytogenes</i> DP-L4384 (S44A-LLO L461T).	Brockstedt, <i>et al.</i> (2004) Proc. Natl. Acad. Sci. USA 101:13832-13837; supporting information.
<i>L. monocytogenes</i> . Mutation in lipote protein ligase (LplA1).	O'Riordan, <i>et al.</i> (2003) Science 302:462-464.
<i>L. monocytogenes</i> DP-L4017 (10403S hly (L461T) point mutation in hemolysin gene.	U.S. Provisional Pat. Appl. Ser. No. 60/490,089 filed July 24, 2003.
<i>L. monocytogenes</i> EGD.	GenBank Acc. No. AL591824.
<i>L. monocytogenes</i> EGD-e.	GenBank Acc. No. NC_003210. ATCC Acc. No. BAA-679.
<i>L. monocytogenes</i> strain EGD, complete genome, segment 3/12	GenBank Acc. No. AL591975
<i>L. monocytogenes</i> .	ATCC Nos. 13932; 15313; 19111-19120; 43248-43251; 51772-51782.
<i>L. monocytogenes</i> DP-L4029 deleted in <i>uvrAB</i> .	U.S. Provisional Pat. Appl. Ser. No. 60/541,515 filed February 2, 2004; U.S. Provisional Pat. Appl. Ser. No. 60/490,080 filed July 24, 2003.
<i>L. monocytogenes</i> DP-L4029 deleted in <i>uvrAB</i> treated with a psoralen.	U.S. Provisional Pat. Appl. Ser. No. 60/541,515 filed February 2, 2004.
<i>L. monocytogenes</i> delta <i>actA</i> delta <i>inlB</i> delta <i>uvrAB</i>	Brockstedt (2005) Nature Medicine and KBMA patent
<i>L. monocytogenes</i> delta <i>actA</i> delta <i>inlB</i> delta <i>uvrAB</i> treated with psoralen	Brockstedt (2005) Nature Medicine and KBMA patent

<i>L. monocytogenes</i> delta <i>actA</i> delta <i>inlB</i> delta <i>uvrAB prfA(G155S)</i>	Lauer et al, (2008) Infect. Immun. And WO 2009/143085
<i>L. monocytogenes</i> delta <i>actA</i> delta <i>inlB</i> delta <i>uvrAB prfA(G155S)</i> treated with psoralen	Lauer et al, (2008) Infect. Immun. And WO 2009/143085
<i>L. monocytogenes</i> ActA-/inlB- double mutant.	Deposited with ATCC on October 3, 2003. Acc. No. PTA-5562.
<i>L. monocytogenes</i> <i>lplA</i> mutant or <i>hly</i> mutant.	U.S. Pat. Applic. No. 20040013690 of Portnoy, <i>et al.</i>
<i>L. monocytogenes</i> DAL/DAT double mutant.	U.S. Pat. Applic. No. 20050048081 of Frankel and Portnoy.
<i>L. monocytogenes</i> str. 4b F2365.	GenBank Acc. No. NC_002973.
<i>Listeria ivanovii</i>	ATCC No. 49954
<i>Listeria innocua</i> Clip11262.	GenBank Acc. No. NC_003212; AL592022.
<i>Listeria innocua</i> , a naturally occurring hemolytic strain containing the PrfA-regulated virulence gene cluster.	Johnson, <i>et al.</i> (2004) Appl. Environ. Microbiol. 70:4256-4266.
<i>Listeria seeligeri</i> .	Howard, <i>et al.</i> (1992) Appl. Environ. Microbiol. 58:709-712.
<i>Listeria innocua</i> with <i>L. monocytogenes</i> pathogenicity island genes.	Johnson, <i>et al.</i> (2004) Appl. Environ. Microbiol. 70:4256-4266.
<i>Listeria innocua</i> with <i>L. monocytogenes</i> internalin A gene, e.g., as a plasmid or as a genomic nucleic acid.	See, e.g., Lingnau, <i>et al.</i> (1995) Infection Immunity 63:3896-3903; Gaillard, <i>et al.</i> (1991) Cell 65:1127-1141).

The present invention encompasses reagents and methods that comprise the above *Listerial* strains, as well as these strains that are modified, e.g., by a plasmid and/or by genomic integration, to contain a nucleic acid encoding one of, or any combination of, the following genes: hly (LLO; listeriolysin); iap (p60); inlA; inlB; inlC; dal (alanine racemase); daaA (dat; D-amino acid aminotransferase); plcA; plcB; ActA; or any nucleic acid that mediates growth, spread, breakdown of a single walled vesicle, breakdown of a double walled vesicle, binding to a host cell, uptake by a host cell. The present invention is not to be limited by the particular strains disclosed above.

[0113] Targeting antigens to endocytic receptors on professional antigen-presenting cells (APCs) also represents an attractive strategy to enhance the efficacy of vaccines. Such APC-targeted vaccines have an exceptional ability to guide exogenous protein antigens into vesicles that efficiently process the antigen for major histocompatibility complex class I and class II presentation. Efficient targeting not only requires high specificity for the receptor that is abundantly expressed on the surface of APCs, but also the ability to be rapidly internalised and loaded into compartments that contain elements of the antigen-processing machinery. In these embodiments, the antigens of the present invention are provided as fusion constructs which include an immunogenic EGFRvIII-derived antigen polypeptide and a desired endocytic receptor-targeting moiety. Suitable APC endocytic receptors include DEC-205, mannose receptor, CLEC9, Fc receptor. This list is not meant to be limiting. A receptor-targeting moiety may be coupled to an immunogenic EGFRvIII-derived antigen polypeptide by recombinant or using chemical crosslinking.

[0114] 4. Therapeutic compositions.

[0115] The vaccine compositions described herein can be administered to a host, either alone or in combination with a pharmaceutically acceptable excipient, in an amount sufficient to induce an appropriate immune response. The immune response can comprise, without limitation, specific immune response, non specific immune response, both specific and non specific response, innate response, primary immune response, adaptive immunity, secondary immune response, memory immune response, immune cell activation, immune cell proliferation, immune cell differentiation, and cytokine

expression. The vaccines of the present invention can be stored, *e.g.*, frozen, lyophilized, as a suspension, as a cell paste, or complexed with a solid matrix or gel matrix.

[0116] In certain embodiments, after the subject has been administered an effective dose of a vaccine containing the immunogenic EGFRvIII-derived antigen polypeptides to prime the immune response, a second vaccine is administered. This is referred to in the art as a “prime-boost” regimen. In such a regimen, the compositions and methods of the present invention may be used as the “prime” delivery, as the “boost” delivery, or as both a “prime” and a “boost.”

[0117] As an example, a first vaccine comprised of killed but metabolically active *Listeria* that encodes and expresses the antigen polypeptide(s) may be delivered as the “prime,” and a second vaccine comprised of attenuated (live or killed but metabolically active) *Listeria* that encodes the antigen polypeptide(s) may be delivered as the “boost.” It should be understood, however, that each of the prime and boost need not utilize the methods and compositions of the present invention. Rather, the present invention contemplates the use of other vaccine modalities together with the bacterial vaccine methods and compositions of the present invention. The following are examples of suitable mixed prime-boost regimens: a DNA (*e.g.*, plasmid) vaccine prime/bacterial vaccine boost; a viral vaccine prime/bacterial vaccine boost; a protein vaccine prime/bacterial vaccine boost; a DNA prime/bacterial vaccine boost plus protein vaccine boost; a bacterial vaccine prime/DNA vaccine boost; a bacterial vaccine prime/viral vaccine boost; a bacterial vaccine prime/protein vaccine boost; a bacterial vaccine prime/bacterial vaccine boost plus protein vaccine boost; etc. This list is not meant to be limiting

[0118] The prime vaccine and boost vaccine may be administered by the same route or by different routes. The term “different routes” encompasses, but is not limited to, different sites on the body, for example, a site that is oral, non-oral, enteral, parenteral, rectal, intranode (lymph node), intravenous, arterial, subcutaneous, intramuscular, intratumor, peritumor, infusion, mucosal, nasal, in the cerebrospinal space or cerebrospinal fluid, and so on, as well as by different modes, for example, oral, intravenous, and intramuscular.

[0119] An effective amount of a prime or boost vaccine may be given in one dose, but is not restricted to one dose. Thus, the administration can be two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more, administrations of the vaccine. Where there is more than one administration of a vaccine or vaccines in the present methods, the administrations can be spaced by time intervals of one minute, two minutes, three, four, five, six, seven, eight, nine, ten, or more minutes, by intervals of about one hour, two hours, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, and so on. In the context of hours, the term “about” means plus or minus any time interval within 30 minutes. The administrations can also be spaced by time intervals of one day, two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, and combinations thereof. The invention is not limited to dosing intervals that are spaced equally in time, but encompass doses at non-equal intervals, such as a priming schedule consisting of administration at 1 day, 4 days, 7 days, and 25 days, just to provide a non-limiting example.

[0120] In certain embodiments, administration of the boost vaccination can be initiated at about 5 days after the prime vaccination is initiated; about 10 days after the prime vaccination is initiated; about 15 days; about 20 days; about 25 days; about 30 days; about 35 days; about 40 days; about 45 days; about 50 days; about 55 days; about 60 days; about 65 days; about 70 days; about 75 days; about 80 days, about 6 months, and about 1 year after administration of the prime vaccination is initiated. Preferably one or both of the prime and boost vaccination comprises delivery of a composition of the present invention.

[0121] A “pharmaceutically acceptable excipient” or “diagnostically acceptable excipient” includes but is not limited to, sterile distilled water, saline, phosphate buffered solutions, amino acid based buffers, or bicarbonate buffered solutions. An excipient selected and the amount of excipient used will depend upon the mode of administration. Administration may be oral, intravenous, subcutaneous, dermal, intradermal, intramuscular, mucosal, parenteral, intraorgan, intralesional, intranasal, inhalation, intraocular, intramuscular, intravascular, intranodal, by scarification, rectal, intraperitoneal, or any one or combination of a variety of well-known routes of

administration. The administration can comprise an injection, infusion, or a combination thereof.

[0122] Administration of the vaccine of the present invention by a non oral route can avoid tolerance. Methods are known in the art for administration intravenously, subcutaneously, intramuscularly, intraperitoneally, orally, mucosally, by way of the urinary tract, by way of a genital tract, by way of the gastrointestinal tract, or by inhalation.

[0123] An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the route and dose of administration and the severity of side effects. Guidance for methods of treatment and diagnosis is available (see, e.g., Maynard, et al. (1996) A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, FL; Dent (2001) Good Laboratory and Good Clinical Practice, Urch Publ., London, UK).

[0124] The vaccines of the present invention can be administered in a dose, or dosages, where each dose comprises at least 100 bacterial cells/kg body weight or more; in certain embodiments 1000 bacterial cells/kg body weight or more; normally at least 10,000 cells; more normally at least 100,000 cells; most normally at least 1 million cells; often at least 10 million cells; more often at least 100 million cells; typically at least 1 billion cells; usually at least 10 billion cells; conventionally at least 100 billion cells; and sometimes at least 1 trillion cells/kg body weight. The present invention provides the above doses where the units of bacterial administration is colony forming units (CFU), the equivalent of CFU prior to psoralen treatment, or where the units are number of bacterial cells.

[0125] The vaccines of the present invention can be administered in a dose, or dosages, where each dose comprises between 10^7 and 10^8 bacteria per 70 kg body weight (or per 1.7 square meters surface area; or per 1.5 kg liver weight); 2×10^7 and 2×10^8 bacteria per 70 kg body weight (or per 1.7 square meters surface area; or per 1.5 kg liver weight); 5×10^7 and 5×10^8 bacteria per 70 kg body weight (or per 1.7 square meters surface area; or per 1.5 kg liver weight); 10^8 and 10^9 bacteria per 70 kg body weight (or per 1.7 square meters surface area; or per 1.5 kg liver weight); between 2.0×10^8 and 2.0×10^9 bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight);

between 5.0×10^8 to 5.0×10^9 bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 10^9 and 10^{10} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 2×10^9 and 2×10^{10} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 5×10^9 and 5×10^{10} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 10^{11} and 10^{12} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 2×10^{11} and 2×10^{12} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 5×10^{11} and 5×10^{12} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 10^{12} and 10^{13} bacteria per 70 kg (or per 1.7 square meters surface area); between 2×10^{12} and 2×10^{13} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 5×10^{12} and 5×10^{13} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 10^{13} and 10^{14} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 2×10^{13} and 2×10^{14} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); 5×10^{13} and 5×10^{14} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 10^{14} and 10^{15} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 2×10^{14} and 2×10^{15} bacteria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); and so on, wet weight.

[0126] Also provided is one or more of the above doses, where the dose is administered by way of one injection every day, one injection every two days, one injection every three days, one injection every four days, one injection every five days, one injection every six days, or one injection every seven days, where the injection schedule is maintained for, e.g., one day only, two days, three days, four days, five days, six days, seven days, two weeks, three weeks, four weeks, five weeks, or longer. The invention also embraces combinations of the above doses and schedules, e.g., a relatively large initial bacterial dose, followed by relatively small subsequent doses, or a relatively small initial dose followed by a large dose.

[0127] A dosing schedule of, for example, once/week, twice/week, three times/week, four times/week, five times/week, six times/week, seven times/week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, and the

like, is available for the invention. The dosing schedules encompass dosing for a total period of time of, for example, one week, two weeks, three weeks, four weeks, five weeks, six weeks, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, and twelve months.

[0128] Provided are cycles of the above dosing schedules. The cycle can be repeated about, e.g., every seven days; every 14 days; every 21 days; every 28 days; every 35 days; 42 days; every 49 days; every 56 days; every 63 days; every 70 days; and the like. An interval of non dosing can occur between a cycle, where the interval can be about, e.g., seven days; 14 days; 21 days; 28 days; 35 days; 42 days; 49 days; 56 days; 63 days; 70 days; and the like. In this context, the term “about” means plus or minus one day, plus or minus two days, plus or minus three days, plus or minus four days, plus or minus five days, plus or minus six days, or plus or minus seven days.

[0129] The present invention encompasses a method of administering *Listeria* that is oral. Also provided is a method of administering *Listeria* that is intravenous. Moreover, what is provided is a method of administering *Listeria* that is oral, intramuscular, intravenous, intradermal and/or subcutaneous. The invention supplies a *Listeria* bacterium, or culture or suspension of *Listeria* bacteria, prepared by growing in a medium that is meat based, or that contains polypeptides derived from a meat or animal product. Also supplied by the present invention is a *Listeria* bacterium, or culture or suspension of *Listeria* bacteria, prepared by growing in a medium that does not contain meat or animal products, prepared by growing on a medium that contains vegetable polypeptides, prepared by growing on a medium that is not based on yeast products, or prepared by growing on a medium that contains yeast polypeptides.

[0130] Methods for co-administration with an additional therapeutic agent are well known in the art (Hardman, et al. (eds.) (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill, New York, NY; Poole and Peterson (eds.) (2001) Pharmacotherapeutics for Advanced Practice: A Practical Approach, Lippincott, Williams & Wilkins, Phila., PA; Chabner and Longo (eds.) (2001) Cancer Chemotherapy and Biotherapy, Lippincott, Williams & Wilkins, Phila., PA).

[0131] Additional agents which are beneficial to raising a cytolytic T cell response may be used as well. Such agents are termed herein carriers. These include, without

limitation, B7 costimulatory molecule, interleukin-2, interferon- γ , GM-CSF, CTLA-4 antagonists, OX-40/OX-40 ligand, CD40/CD40 ligand, sargramostim, levamisol, vaccinia virus, Bacille Calmette-Guerin (BCG), liposomes, alum, Freund's complete or incomplete adjuvant, detoxified endotoxins, mineral oils, surface active substances such as lipolecithin, pluronic polyols, polyanions, peptides, and oil or hydrocarbon emulsions. Carriers for inducing a T cell immune response which preferentially stimulate a cytolytic T cell response versus an antibody response are preferred, although those that stimulate both types of response can be used as well. In cases where the agent is a polypeptide, the polypeptide itself or a polynucleotide encoding the polypeptide can be administered. The carrier can be a cell, such as an antigen presenting cell (APC) or a dendritic cell. Antigen presenting cells include such cell types as macrophages, dendritic cells and B cells. Other professional antigen-presenting cells include monocytes, marginal zone Kupffer cells, microglia, Langerhans' cells, interdigitating dendritic cells, follicular dendritic cells, and T cells. Facultative antigen-presenting cells can also be used. Examples of facultative antigen-presenting cells include astrocytes, follicular cells, endothelium and fibroblasts. The carrier can be a bacterial cell that is transformed to express the polypeptide or to deliver a polynucleotide which is subsequently expressed in cells of the vaccinated individual. Adjuvants, such as aluminum hydroxide or aluminum phosphate, can be added to increase the ability of the vaccine to trigger, enhance, or prolong an immune response. Additional materials, such as cytokines, chemokines, and bacterial nucleic acid sequences, like CpG, a toll-like receptor (TLR) 9 agonist as well as additional agonists for TLR 2, TLR 4, TLR 5, TLR 7, TLR 8, TLR9, including lipoprotein, LPS, monophosphoryl lipid A, lipoteichoic acid, imiquimod, resiquimod, and other like immune modulators used separately or in combination with the described compositions are also potential adjuvants. Other representative examples of adjuvants include the synthetic adjuvant QS-21 comprising a homogeneous saponin purified from the bark of *Quillaja saponaria* and *Corynebacterium parvum* (McCune et al., *Cancer*, 1979; 43:1619). It will be understood that the adjuvant is subject to optimization. In other words, the skilled artisan can engage in routine experimentation to determine the best adjuvant to use.

[0132] An effective amount of a therapeutic agent is one that will decrease or ameliorate the symptoms normally by at least 10%, more normally by at least 20%, most normally by at least 30%, typically by at least 40%, more typically by at least 50%, most

typically by at least 60%, often by at least 70%, more often by at least 80%, and most often by at least 90%, conventionally by at least 95%, more conventionally by at least 99%, and most conventionally by at least 99.9%.

[0133] The reagents and methods of the present invention provide a vaccine comprising only one vaccination; or comprising a first vaccination; or comprising at least one booster vaccination; at least two booster vaccinations; or at least three booster vaccinations. Guidance in parameters for booster vaccinations is available. See, e.g., Marth (1997) *Biologicals* 25:199-203; Ramsay, et al. (1997) *Immunol. Cell Biol.* 75:382-388; Gherardi, et al. (2001) *Histol. Histopathol.* 16:655-667; Leroux-Roels, et al. (2001) *Acta Clin. Belg.* 56:209-219; Greiner, et al. (2002) *Cancer Res.* 62:6944-6951; Smith, et al. (2003) *J. Med. Virol.* 70:Suppl.1:S38-S41; Sepulveda-Amor, et al. (2002) *Vaccine* 20:2790-2795).

[0134] Formulations of therapeutic agents may be prepared for storage by mixing with physiologically acceptable carriers, excipients, or stabilizers in the form of, e.g., lyophilized powders, slurries, aqueous solutions or suspensions (see, e.g., Hardman, et al. (2001) *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, McGraw-Hill, New York, NY; Gennaro (2000) *Remington: The Science and Practice of Pharmacy*, Lippincott, Williams, and Wilkins, New York, NY; Avis, et al. (eds.) (1993) *Pharmaceutical Dosage Forms: Parenteral Medications*, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) *Pharmaceutical Dosage Forms: Tablets*, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) *Pharmaceutical Dosage Forms: Disperse Systems*, Marcel Dekker, NY; Weiner and Kotkoskie (2000) *Excipient Toxicity and Safety*, Marcel Dekker, Inc., New York, NY).

[0135] Examples

[0136] The following examples serve to illustrate the present invention. These examples are in no way intended to limit the scope of the invention.

[0137] Example 1. Bacterial Strains and Antigen Selection

[0138] Lm vaccine strains were constructed in two strain backgrounds, live-attenuated (Lm11, aka Lm $\Delta actA/\Delta inlB$) and KBMA PrfA* (Lm677, aka Lm $\Delta actA/\Delta inlB/\Delta uvrAB/prfA$ G155S). Expression cassettes were designed to contain 1 and 5

copies of the sequence PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 4) (denoted PvIII in Fig. 1), each copy flanked by a proteasome cleavage sequence (black boxes in Fig. 1). The expression cassettes were codon optimized for expression in *L. monocytogenes* and cloned as BamHI-SpeI fragments downstream from the *actA* promoter and in-frame with the 100 amino terminal acids of ActA (“ActA-N100”) and tagged at the carboxy terminus with SIINFEKL (SL8), a surrogate T-cell epitope that facilitates evaluation of expression and secretion of encoded heterologous antigens. The constructs were cloned into a derivative of the pPL2 integration vector and stably integrated at the *tRNA^{Arg}* locus of the bacterial chromosome.

[0139] The tested strains are summarized in the following table:

Strain	Construct	Background
BH137	ActAN100-AH1A5-OVA	Lm11 ($\Delta actA \Delta inlB$)
Lm11	Negative control	
PL712	ActAN100-PepVIIIx5-SL8	Lm11
PL714	ActAN100-PepVIIIx5-SL8	Lm677 (prfA*)
PL716	ActAN100-PepVIIIx1-SL8	Lm11
PL717	ActAN100-PepVIIIx1-SL8	Lm677 (prfA*)

[0140] Example 2. *In vitro* Cell Culture

[0141] J774 cells were cultured in T cell media (RPMI media (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Hyclone, Logan, UT), penicillin/streptomycin (Mediatech, Manassas, VA), 1x non-essential amino acids (Mediatech, Manassas, VA), 2mM L-glutamine (Mediatech, Manassas, VA), HEPES buffer (Invitrogen, Carlsbad, CA), 1 mM sodium pyruvate (Sigma, St. Louis, MO), and 50 μ M β -mercaptoethanol (Sigma, St. Louis, MO)). B3Z hybridoma cells were cultured in T cell media without penicillin/streptomycin.

[0142] Example 4. Immunizations

[0143] 6-12 week old female C3H/HeJ mice were obtained from Charles River Laboratories (Wilmington, MA). Studies were performed under animal protocols approved by the appropriate Institutional Animal Care and Use Committee. Live-

attenuated bacteria were prepared for immunization from overnight cultures grown in yeast extract media. Bacteria were diluted in Hank's balanced salt solution (HBSS) for injection. Live-attenuated bacteria were administered i.v. into tail vein in 200 μ L volume. Injection stocks of live-attenuated bacteria were plated to confirm colony forming units (CFU). Animals were primed and boosted female with 1×10^7 CFU *Lm* $\Delta actA \Delta inlB prfA^* - 5xEGFRvIII_{20-40}$ separated by 30 days, and the frequency of EGFRvIII-specific CD8+ T cells determined by intracellular cytokine staining. (Fig. 3).

[0144] Example 5. Assessment of Antigen Expression and Immune Response

[0145] a. Western blots

[0146] Western blots from broth culture were performed on equivalent amounts of TCA-precipitated supernatants of bacterial cultures grown in yeast extract media to an OD₆₀₀ of 0.7 (late log). For western blots from *Lm* infected DC2.4 cells were inoculated with a multiplicity of infection (MOI) of 10 for 1 hour, the cells were washed 3 \times with PBS and DMEM media supplemented with 50 μ g/mL gentamycin. Cells were harvested at 7 hours post infection. Cells were lysed with SDS sample buffer, collected and run on 4-12% polyacrylamide gels and transferred to nitrocellulose membranes for western blot analysis. All western blots utilized a polyclonal antibody raised against the mature N-terminus of the ActA protein and were normalized to p60 expression (an unrelated *Lm* protein) with an anti-p60 monoclonal antibody. Antigen detection was visualized either by enhanced chemiluminescence (ECL) or visualized and quantitated with the Licor Odyssey IR detection system (Fig. 2)

[0147] b. B3Z assay

[0148] DC2.4 cells were infected with the selected strains, and incubated with the OVA₂₅₇₋₂₆₄-specific T cell hybridoma, B3Z. Presentation of SIINFEKL epitope on H-2 K^b class I molecules was assessed by measuring β -galactosidase expression using a chromogenic substrate (Fig. 4).

[0149] c. Reagents for flow cytometry

[0150] CD4 FITC (clone GK1.5) and MHC class II FITC (clone M5/114.15.2) were purchased from eBioscience (San Diego, CA). CD8a antibody PerCP (clone 53-6.7) was

purchased from BD Biosciences (San Jose, CA). The Kk-EEKKGNYV (SEQ ID NO: 3) tetramer was folded by the NIH Tetramer Core and conjugated to APC.

[0151] d. Tetramer Staining of EGFRvIII-Specific T Cells

[0152] Splenocytes (lymphocytes from the spleen) were incubated with anti-CD4, anti-CD8, anti-MHC class II and Kk-EGFRvIII tetramer for 15 minutes at room temperature. Cells were washed three times with HBSS. Samples were acquired using a LSRII flow cytometer (BD Biosciences). Data were gated to include exclusively CD8+, CD4-class II- events, then the percentage of these cells binding Kk-EEKKGNYV (SEQ ID NO: 3) tetramer was determined. Data was analyzed using FlowJo software (Treestar, Ashland, OR).

[0153] Example 6: Results

[0154] As can be seen from Fig. 2, all of the EGFRvIII₂₀₋₄₀ constructs were detected within J774 macrophages. Furthermore, we found that increasing the copies of EGFRvIII₂₀₋₄₀ appears to enhance intracellular secretion (Fig. 2). The amount of 5xEGFRvIII₂₀₋₄₀ secreted exceeded that of the “gold-standard” ovalbumin. In animals, receiving the 5xEGFRvIII₂₀₋₄₀ construct, greater than 30% of the CD8+ T cells in the spleen were EGFRvIII-specific 5 days following boost immunization (Fig. 3). All of the EGFRvIII₂₀₋₄₀ constructs tested are recognized by the B3Z T cell, indicating successful expression and presentation of T cell epitopes by the *L. monocytogenes* strains at a level roughly equivalent to the model ovalbumin antigen (Fig. 4).

[0155] These data suggest that an EGFRvIII₂₀₋₄₀ expression construct, and particularly a multimeric EGFRvIII₂₀₋₄₀ expression construct, is well suited for use within this *L. monocytogenes* vaccine platform.

[0156] Example 7: Evaluating an immune response with EEKKGNYV (SEQ ID NO: 3)

[0157] Precise identification of class I restricted epitopes provides an optimized method for assessing immunogenicity in vivo, simplifying comparisons of our vaccine candidates. To identify mouse class I-restricted epitopes, as well as to perform a cursory evaluation of immunogenicity, C57BL/6 (H-2^b), BALB/c (H-2^d), C3H/HeJ (H-2^k) and SJL (H-2^s) mice were immunized with 1x10⁷ colony forming units (CFU) of each

EGFRvIII₂₀₋₄₀ expressing strain and the frequency and specificity of EGFRvIII-specific T cells was determined by IFN- γ intracellular cytokine staining (ICS). This library uses 15-AA peptides overlapping by 14-AA, possible due to the short sequence of the EGFRvIII₂₀₋₄₀ peptide in our vaccine, and desirable due to the known N-terminal processing issues associated with these libraries. The greatest response was in the C3H mouse strain (H-2^k), where >1% of total CD8+ T cells in the spleen responded to one of the 15-AA peptides (data not shown).

[0158] To confirm this finding and refine the exact sequence of the class I-binding peptide, a cohort of C3H mice were primed and boosted with the Lm-EGFRvIIIx5 strain, and then screened again with the peptide library. In addition, we included refined peptides from the 15-mer identified in the primary immunogenicity assay. CD8+ T cells from these primed and boosted mice recognized several of the 15-AA peptides, and reactivity was dependent upon two N-terminal glutamic acid residues. Assuming these two glutamic acid residues were necessary for MHC binding, we used 7-, 8- and 9-mers from this sequence and screened for reactivity (Fig. 5).

[0159] Identification of a class I-restricted EGFRvIII-epitope in C3H mice. Female C3H mice were primed and boosted with Lm-EGFRvIIIx5, and then five days later spleens were harvested and tested for reactivity with the EGFRvIII peptide library, as well as 7-, 8-, and 9-mers derived from the peptide with the greatest reactivity in a preliminary screen. Data represent the %IFN- γ + events within the CD8+ T cell gate. These experiments demonstrated that the 8-AA peptide EEKKGNYV (SEQ ID NO: 3) is recognized by CD8+ T cells from C3H mice immunized

[0160] TAP-deficient T2 cells are unable to load class I molecules with peptides, leading to instability and recycling from the cell surface. When exogenous peptides are added that can bind the expressed MHC molecule, that molecule is stabilized on the cell surface with Lm-EGFRvIII. To confirm k^k binding of the EEKKGNYV (SEQ ID NO: 3) peptide, A T2 cell assay which measures such induction of class I expression upon peptide binding was used substantially as described by Hansen and Myers (2003) Peptide induction of surface expression of class I MHC, p. 18.11.1-18.11.8 in J. E. Colgan, A. M. Kruisbeer, D. H. Margules, and W. Strober (ed.), Current Protocols in Immunology, vol. 4. John Wiley & Sons, New York, N.Y. K^k-expressing T2 cells were incubated overnight with the concentration of each EGFRvIII peptide as indicated in Fig. 6. Cells were

washed and stained for surface K^k expression using a class I-specific antibody. The data demonstrate that EEKKGNYV binds K^k and is optimal relative to the larger peptides that also contain this sequence. These data support the use of the defined EEKKGNYV peptide for *ex vivo* cellular assays based on its ability to bind K^k and provide MHC-peptide complexes that can be recognized by CD8+ T cells.

[0161] Using this defined class I restricted peptide, we compared the magnitude of the primary EGFRvIII-specific CD8+ T cell response after immunization with each strain. Female C3H mice were immunized with 1×10^5 CFU of the 1x or 5x strains, and seven days later spleens were harvested and the frequency of EGFRvIII₂₆₋₃₃-specific CD8+ T cells determined by ICS. Consistent with our hypothesis, the inclusion of multiple copies of EGFRvIII₂₀₋₄₀ led to enhanced CD8+ T cell priming relative to the single copy variant (Fig. 7).

[0162] These data demonstrate the ability to express a construct encoding repeating epitope sequences, but altering codon usage to maximize genetic stability and antigen expression/secretion. This approach allows for increased potency without increasing potential risks to the patient (i.e. by giving large doses of vaccine).

[0163] One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.

[0164] It will be readily apparent to a person skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

[0165] All patents and publications mentioned in the specification are indicative of the levels of those of ordinary skill in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

[0166] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[0167] Other embodiments are set forth within the following claims.

We claim:

1. A method of inducing a T-cell response to EGFRvIII in a subject, said method comprising:

recombinantly expressing at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), in said subject under conditions selected to induce said T cell response in said subject.

2. The method of claim 1 wherein said plurality of EGFRvIII polypeptide sequences comprise one or more amino acid sequences selected from the group consisting of LEEKKGNYV (SEQ ID NO: 4), LEEKKGNYVVDH (SEQ ID NO: 2), and PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).

3. The method of claim 2 wherein said plurality of EGFRvIII polypeptide sequences comprise at least three copies of PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).

4. The method of claim 2 wherein said plurality of EGFRvIII polypeptide sequences comprise at least five copies of PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).

5. The method of any one of claims 1-4, wherein each EGFRvIII polypeptide sequence is flanked by a sequence which is configured to be cleaved by the proteasome.

6. The method of claim 5, wherein each EGFRvIII polypeptide sequence is flanked by a sequence selected from the group consisting of ASKVL↓ADGSVK; ASKVA↓GDGSIK; LSKVL↓ADGSVK; LAKSL↓ADLAVK; ASVVA↓GIGSIA; GVEKI↓NAANKG; and DGSKKA↓GDGNKK (SEQ ID NOS: 6-12), wherein each arrow represents an EGFRvIII polypeptide sequence.

7. The method of any one of claims 1-6, wherein the immunogenic polypeptide is expressed in said subject by administering a *Listeria monocytogenes* bacterium comprising a nucleic acid sequence encoding said immunogenic polypeptide integrated into the genome of said bacterium operably linked to control sequences which cause the expression of the immunogenic polypeptide in the subject.

8. The method of claim 7, wherein the bacterium is an *actA* deletion mutant or an *actA* insertion mutant, an *inlB* deletion mutant or an *inlB* insertion mutant or a $\Delta actA/\Delta inlB$ mutant comprising both an *actA* deletion or an *actA* insertion and an *inlB* deletion or an *inlB* insertion.
9. The method of claim 8, wherein said nucleic acid sequence has been integrated into a virulence gene of said bacterium, and the integration of said nucleic acid sequence disrupts expression of the virulence gene or disrupts a coding sequence of the virulence gene.
10. The method of claim 9, wherein the virulence gene is *actA* or *inlB*.
11. The method of any one of claims 1-10, wherein the bacterium is an attenuated *Listeria monocytogenes*.
12. The method of claim 11, wherein the bacterium is *Lm* $\Delta actA/\Delta inlB$.
13. The method of claim 12, wherein the bacterium further comprises a genetic mutation that attenuates the ability of the bacterium to repair nucleic acid.
14. The method of claim 13, wherein the genetic mutation is in one or more genes selected from *phrB*, *uvrA*, *uvrB*, *uvrC*, *uvrD* and *recA*.
15. The method of claim 11, wherein the bacterium is a *Listeria monocytogenes prfA* mutant, the genome of which encodes a prfA protein which is constitutively active.
16. The method of claim 11, wherein the bacterium is a killed but metabolically active *Listeria monocytogenes*.
17. The method of claim 16, wherein the bacterium is a *Listeria monocytogenes prfA* mutant, the genome of which encodes a prfA protein which is constitutively active.
18. The method of claim 7, wherein the nucleic acid sequence is codon optimized for expression by *Listeria monocytogenes*.

19. The method of claim any one of claims 7-18, wherein said conditions selected to induce said T cell response in said subject comprise administering said *Listeria monocytogenes* by one or more routes of administration selected from the group consisting of orally, intramuscularly, intravenously, intradermally, and subcutaneously to said subject.

20. The method of any one of claims 1-19, wherein said immunogenic polypeptide is expressed as a fusion protein comprising a secretory signal sequence.

21. The method of claim 20, wherein the secretory signal sequence is a *Listeria monocytogenes* ActA signal sequence.

22. The method of claim 20, wherein said immunogenic polypeptide is expressed as a fusion protein comprising an in frame ActA-N100 sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31, or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence.

23. The method of claim 7, wherein said method comprises administering a *Listeria monocytogenes* expressing a fusion protein comprising:

an ActA-N100 sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31 or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence; and

a plurality of amino acid sequences having the sequence PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5), each of said plurality of amino acid sequences being flanked by a sequence which is configured to be cleaved by the proteasome,

wherein said fusion protein is expressed from a nucleic acid sequence operably linked to a *Listeria monocytogenes* ActA promoter.

24. The method of any one of claims 1-23, wherein said subject has an EGFRvIII-expressing tumor.

25. The method of claim 24, wherein said subject has a glioma.

26. The method of claim one of claims 1-25, wherein said composition, when delivered to said subject, induces an increase in the serum concentration of one or more proteins selected from the group consisting of IL-12p70, IFN- γ , IL-6, TNF α , and MCP-1 at 24 hours following said delivery; and induces a CD4+ and/or CD8+ antigen-specific T cell response against EGFRvIII.
27. A composition comprising:
- a bacterium or virus which comprises a nucleic acid encoding at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3).
28. The composition of claim 27 wherein said plurality of EGFRvIII polypeptide sequences comprise one or more amino acid sequences selected from the group consisting of LEEKKGNYV (SEQ ID NO: 4), LEEKKGNYVVDH (SEQ ID NO: 2), and PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).
29. The composition of claim 28 wherein said plurality of EGFRvIII polypeptide sequences comprise at least three copies of PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).
30. The composition of claim 28 wherein said plurality of EGFRvIII polypeptide sequences comprise at least five copies of PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).
31. The method of any one of claims 27-30, wherein each EGFRvIII polypeptide sequence is flanked by a sequence which is configured to be cleaved by the proteasome.
32. The composition of any one of claims 27-31, wherein the composition comprises a *Listeria monocytogenes* bacterium comprising said nucleic acid integrated into the genome of said bacterium.
33. The composition of claim 32, wherein the bacterium is an *actA* deletion mutant or an *actA* insertion mutant, an *inlB* deletion mutant or an *inlB* insertion mutant or a $\Delta actA/\Delta inlB$ mutant comprising both an *actA* deletion or an *actA* insertion and an *inlB* deletion or an *inlB* insertion.

34. The composition of claim 32, wherein said nucleic acid has been integrated into a virulence gene of said bacterium, and the integration of the polynucleotide disrupts expression of the virulence gene or disrupts a coding sequence of the virulence gene.
35. The composition of claim 34, wherein the virulence gene is *actA* or *inlB*.
36. The composition of claim 32 wherein the bacterium is an attenuated *Listeria monocytogenes*.
37. The composition of claim 36, wherein the bacterium is *Lm* Δ actA/ Δ inlB.
38. The composition of claim 34, wherein the bacterium further comprises a genetic mutation that attenuates the ability of the bacterium to repair nucleic acid.
39. The composition of claim 38, wherein the genetic mutation is in one or more genes selected from *phrB*, *uvrA*, *uvrB*, *uvrC*, *uvrD* and *recA*.
40. The composition of claim 36, wherein the bacterium is a *Listeria monocytogenes* *prfA* mutant, the genome of which encodes a *prfA* protein which is constitutively active.
41. The composition of claim 37, wherein the bacterium is a killed but metabolically active *Listeria monocytogenes*.
42. The composition of claim 32, wherein the bacterium is a *Listeria monocytogenes* *prfA* mutant, the genome of which encodes a *prfA* protein which is constitutively active.
43. The composition of claim 32, wherein the nucleic acid is codon optimized for expression by *Listeria monocytogenes*.
44. The composition of any one of claims 27-43, wherein said composition further comprises a pharmaceutically acceptable excipient.
45. The composition of any one of claims 27-44, wherein said nucleic acid encodes said immunogenic polypeptide as a fusion protein comprising a secretory signal sequence.
46. The composition of claim 45, wherein the secretory signal sequence is a *Listeria monocytogenes* ActA signal sequence.

47. The composition of claim 46, wherein said nucleic acid molecule encodes said immunogenic polypeptide as a fusion protein comprising an in frame ActA-N100 sequence selected from the group consisting of selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31, or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence.

48. The composition any one of claims 32-47, wherein said composition comprises a *Listeria monocytogenes* which comprises a nucleic acid, the sequence of which encodes a fusion protein comprising:

an ActA-N100 sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31 or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence; and

a plurality of amino acid sequences having the sequence PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5), each of said plurality of amino acid sequences being flanked by a sequence which is configured to be cleaved by the proteasome,

wherein said fusion protein is expressed from a nucleic acid sequence operably linked to a *Listeria monocytogenes ActA* promoter.

49. A method of treating an EGFRvIII-expressing malignancy in a subject, said method comprising:

administering to said subject a composition of one of claims 27-48 under conditions selected to induce said T cell response in said subject.

50. A pharmaceutical composition comprising:

the composition of any one of claims 27-49; and

a pharmaceutically acceptable excipient.

51. An isolated nucleic acid molecule encoding at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3).

52. The isolated nucleic acid molecule of claim 51 wherein said plurality of EGFRvIII polypeptide sequences comprise one or more amino acid sequences selected from the group consisting of LEEKKGNYV (SEQ ID NO: 4), LEEKKGNYVVDH (SEQ ID NO: 2), and PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).
53. The isolated nucleic acid molecule of claim 51 wherein said plurality of EGFRvIII polypeptide sequences comprise at least three copies of PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).
54. The isolated nucleic acid molecule of claim 51 wherein said plurality of EGFRvIII polypeptide sequences comprise at least five copies of PASRALEEKKGNYVVDHGSC (SEQ ID NO: 5).
55. The isolated nucleic acid molecule of any one of claims 51-54, wherein each EGFRvIII polypeptide sequence is flanked by a sequence which is configured to be cleaved by the proteasome.
56. The isolated nucleic acid molecule of any one of claims 51-55, wherein the nucleic acid molecule is codon optimized for expression by *Listeria monocytogenes*.
57. The isolated nucleic acid molecule of any one of claims 51-56, wherein said nucleic acid molecule encodes said immunogenic polypeptide as a fusion protein comprising a secretory signal sequence.
58. The isolated nucleic acid molecule of claim 57, wherein the secretory signal sequence is a *Listeria monocytogenes* ActA signal sequence.
59. The isolated nucleic acid molecule of claim 58, wherein said nucleic acid molecule encodes said immunogenic polypeptide as a fusion protein comprising an in frame ActA-N100 sequence selected from the group consisting of selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31, or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence.

60. The isolated nucleic acid molecule of claim 59, wherein said nucleic acid molecule encodes said immunogenic polypeptide as a fusion protein comprising:

an ActA-N100 sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31 or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence; and

a plurality of amino acid sequences having the sequence PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5), each of said plurality of amino acid sequences being flanked by a sequence which is configured to be cleaved by the proteasome,

wherein said nucleic acid molecule is operably linked to a *Listeria monocytogenes ActA* promoter.

61. A recombinantly produced or chemically synthesized polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3).

62. The polypeptide of claim 61 wherein said plurality of EGFRvIII polypeptide sequences comprise one or more amino acid sequences selected from the group consisting of LEEKKGNYV (SEQ ID NO: 4), LEEKKGNYVVTDH (SEQ ID NO: 2), and PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5).

63. The polypeptide of claim 61 wherein said plurality of EGFRvIII polypeptide sequences comprise at least three copies of PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5).

64. The polypeptide of claim 61 wherein said plurality of EGFRvIII polypeptide sequences comprise at least five copies of PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5).

65. The polypeptide of any one of claims 61-64, wherein each EGFRvIII polypeptide sequence is flanked by a sequence which is configured to be cleaved by the proteasome.

66. The polypeptide of any one of claims 61-64, further comprising a moiety configured to target said polypeptide to a cell surface receptor of an antigen-presenting cell.

Fig. 1




Fig. 2




Fig. 3




Fig. 4





Fig. 5







Fig. 6

Fig. 7



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 11/61164

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C12P 21/06, C12N 15/00 (2012.01)

USPC - 435/69.1; 435/320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

USPC: 435/69.1; 435/320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC: 435/69.1; 435/320.1; 514/44R, 514/1.1, 536/23.1, 530/300 (text search)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Electronic data bases: PubWEST (PGPB, EPAB, JPAB, USPTP; Google Scholar; GenCore sequence search (AA)

Search terms: epidermal growth factor receptor class III variant (EGFRvIII); vaccine, cancer breast, lung, proteasome cleavage site or cleavage motif, proteasome degradation, T-cell response, Listeria

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	US 6,224,868 B1 (WONG et al.). 1 May 2001 (01.05.2001). Especially col 2 ln 17-37, Col 3 ln 47-63; claims 1 and 2, SEQ ID NO: 1.	1,2,27,28,51,52,61, 62 ----- 3-6, 29-31, 53-55,63-66
Y	WO 2009/012488 A1 (SCHMITTLING et al.) 22 January 2009 (22.01.2009). Especially para [0028], SEQ ID NO: 15.	3, 4, 29, 30, 53, 54,63, 64
Y	KESMIR et al., Prediction of proteasome cleavage motifs by neural networks. J Protein Eng, April 2002, Vol 15, No 4, Pages 287-296. Especially abstract.	5, 31, 55, 65
Y	BIRKHOLZ et al., Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood, 30 September 2010, Vol 116, No 13, Pages 2277-2285. Especially abstract.	66
Y	NET CHOP. Net Chop 3.1 Server, 3 November 2009 [online]. [Retrieved 7 March 2012]. Retrieved from the internet <URL: http://www.cbs.dtu.dk/services/NetChop/ >. Especially pg 3.	6

 Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

3 March 2012 (03.02.2012)

Date of mailing of the international search report

29 MAR 2012

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 11/61164

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: 7-26, 32-50, and 56-60
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 11/61164

Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:

a. (means)

on paper

in electronic form

b. (time)

in the international application as filed

together with the international application in electronic form

subsequently to this Authority for the purposes of search

2. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

GenCore ver 6.3 SEQ ID NOs: 2,3,4,5,6,7,8,9,10,11